activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	2470263	CHEMBL987182	Inhibition of MARK4 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5754	Homo sapiens	INH	%	10.0
	2470263	CHEMBL987182	Inhibition of MARK4 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL5754	Homo sapiens	INH	%	10.0
Not Evaluated	2476726	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2478565	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL5754	Homo sapiens	Activity		
	2478768	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	14.05	CHEMBL5754	Homo sapiens	Activity	%	14.05
Not Evaluated	2479623	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2479826	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL5754	Homo sapiens	Activity		
Active	2480623	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2480825	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2577244	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2577447	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2593652	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2593918	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2594121	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2594861	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2595064	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2596261	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2596464	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019		Activity			CHEMBL5754	Homo sapiens	Activity		
Not Evaluated	2597733	CHEMBL982754	Binding affinity to human MARK4 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL5754	Homo sapiens	Activity		
	2900456	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900457	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900458	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900459	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900460	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900461	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900462	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1700.0	CHEMBL5754	Homo sapiens	Kd	nM	1700.0
	2900463	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900464	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900465	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900466	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900467	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900468	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900469	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900470	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900471	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900472	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900473	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900474	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900475	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Kd	nM	660.0	CHEMBL5754	Homo sapiens	Kd	nM	660.0
	2900476	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900477	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900478	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900479	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900480	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900481	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	370.0	CHEMBL5754	Homo sapiens	Kd	nM	370.0
	2900482	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900483	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900484	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900485	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900486	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900487	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900488	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	5.4	CHEMBL5754	Homo sapiens	Kd	nM	5.4
	2900489	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	2000.0	CHEMBL5754	Homo sapiens	Kd	nM	2000.0
	2900490	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	3600.0	CHEMBL5754	Homo sapiens	Kd	nM	3600.0
	2900491	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4900.0	CHEMBL5754	Homo sapiens	Kd	nM	4900.0
	2900492	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2900493	CHEMBL1051302	Binding constant for MARK4 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	2921274	CHEMBL1047442	Inhibition of MARK4 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	3213963	CHEMBL1116711	Inhibition of MARK4 at 5 uM	B	O=C(Nc1ccccc1Cl)c1cnc2ccc(C3CCNCC3)cn12.O=C(O)C(=O)O		CHEMBL1077739	=	Inhibition	%	11.0	CHEMBL5754	Homo sapiens	INH	%	11.0
	3224884	CHEMBL1100962	Inhibition of MARK4 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3226263	CHEMBL1100962	Inhibition of MARK4 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3260067	CHEMBL1104324	Inhibition of MARK4 at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2nccc(Nc3cccc(Br)c3)c2c1		CHEMBL1089524	=	Activity	%	75.0	CHEMBL5754	Homo sapiens	Activity	%	75.0
	3261406	CHEMBL1104324	Inhibition of MARK4 at 10 uM assessed as residual activity by [33P]ATP radioactive filter binding assay relative to control	B	CN(C)CCCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL1088901	=	Activity	%	74.0	CHEMBL5754	Homo sapiens	Activity	%	74.0
	3332019	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3333434	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3334839	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3336259	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3337579	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3338910	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3339163	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3340467	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3341801	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3343248	CHEMBL1166069	Inhibition of MARK4 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	3358660	CHEMBL1174902	Inhibition of MARK4 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	87.0	CHEMBL5754	Homo sapiens	INH	%	87.0
	3359102	CHEMBL1174902	Inhibition of MARK4 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	85.0	CHEMBL5754	Homo sapiens	INH	%	85.0
	3445191	CHEMBL1244503	Binding affinity to MARK4	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	120.0	CHEMBL5754	Homo sapiens	Kd	nM	120.0
	3448495	CHEMBL1244503	Binding affinity to MARK4	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	3448983	CHEMBL1244503	Binding affinity to MARK4	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	370.0	CHEMBL5754	Homo sapiens	Kd	nM	370.0
	3449458	CHEMBL1244503	Binding affinity to MARK4	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	3600.0	CHEMBL5754	Homo sapiens	Kd	nM	3600.0
	3449728	CHEMBL1244503	Binding affinity to MARK4	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	3450132	CHEMBL1244503	Binding affinity to MARK4	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	3451049	CHEMBL1244503	Binding affinity to MARK4	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	uM	10.0
	5089645	CHEMBL1633365	Inhibition of MARK4 at 10 uM	B	C(#Cc1n[nH]c2ccccc12)c1ccncc1		CHEMBL1631892	>=	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	5132613	CHEMBL1648752	Inhibition of MARK4 assessed as residual activity at 10 uM	B	CN(C)C/C=C/C(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641990	=	Activity	%	82.0	CHEMBL5754	Homo sapiens	Activity	%	82.0
	5133756	CHEMBL1648752	Inhibition of MARK4 assessed as residual activity at 10 uM	B	CN(C)CCCC(=O)Nc1ccc2c(C#N)cnc(Nc3cccc(Br)c3)c2c1		CHEMBL1641989	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	5133915	CHEMBL1648752	Inhibition of MARK4 assessed as residual activity at 10 uM	B	CN1CCN(CCC(=O)Nc2ccc3c(C#N)cnc(Nc4cccc(Br)c4)c3c2)CC1		CHEMBL1641992	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	6341087	CHEMBL1828400	Activity of MARK4 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	6352235	CHEMBL1825842	Inhibition of MARK4 assessed as residual activity at 10 uM by radioactivity assay in presence of 50 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	72.0	CHEMBL5754	Homo sapiens	Activity	%	72.0
	7567100	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7567559	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7568030	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7568498	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7568930	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	2000.0	CHEMBL5754	Homo sapiens	Kd	nM	2000.0
	7569073	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7569533	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7570005	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7570468	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7570895	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	3600.0	CHEMBL5754	Homo sapiens	Kd	nM	3600.0
	7571049	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7571506	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7571982	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7572445	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7573030	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7573487	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7573963	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	5300.0	CHEMBL5754	Homo sapiens	Kd	nM	5300.0
	7574398	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	12.0	CHEMBL5754	Homo sapiens	Kd	nM	12.0
	7575008	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	2000.0	CHEMBL5754	Homo sapiens	Kd	nM	2000.0
	7575469	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7575963	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	370.0	CHEMBL5754	Homo sapiens	Kd	nM	370.0
	7576371	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7576982	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7577441	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7577477	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7577947	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7578352	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	970.0	CHEMBL5754	Homo sapiens	Kd	nM	970.0
	7578990	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7579364	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7579846	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	210.0	CHEMBL5754	Homo sapiens	Kd	nM	210.0
	7580315	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7580718	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7581736	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7582207	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7582671	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7583071	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4900.0	CHEMBL5754	Homo sapiens	Kd	nM	4900.0
	7583252	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7583649	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7584094	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7584565	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7585027	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	89.0	CHEMBL5754	Homo sapiens	Kd	nM	89.0
	7585431	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7585582	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7585990	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7586436	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7586907	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7587361	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7587543	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7587962	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7588415	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7588886	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7589508	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7589932	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	120.0	CHEMBL5754	Homo sapiens	Kd	nM	120.0
	7590399	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7590882	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7591481	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7591903	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1700.0	CHEMBL5754	Homo sapiens	Kd	nM	1700.0
	7592375	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7592406	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7592859	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7593448	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7593883	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7594386	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7594838	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7595416	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7595892	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7596363	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7596810	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7597399	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7597872	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7598342	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL5754	Homo sapiens	Kd	nM	10000.0
	7598784	CHEMBL1908837	Binding constant for MARK4 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	5.4	CHEMBL5754	Homo sapiens	Kd	nM	5.4
	7969748	CHEMBL1931447	Inhibition of MARK4 assessed as residual activity at 10 uM using [33P-ATP] by radiometric filter binding assay	B	Cc1ccc(F)cc1-c1nc2[nH]nc(N)c2c2c1CCCC2		CHEMBL1927262	=	Activity	%	74.0	CHEMBL5754	Homo sapiens	Activity	%	74.0
	8061269	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.06	CHEMBL5754	Homo sapiens	Inhibition	%	0.06
	8061446	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	3.25	CHEMBL5754	Homo sapiens	Inhibition	%	3.25
	8061777	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.51	CHEMBL5754	Homo sapiens	Inhibition	%	0.51
	8061968	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.67	CHEMBL5754	Homo sapiens	Inhibition	%	1.67
	8062192	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	6.49	CHEMBL5754	Homo sapiens	Inhibition	%	6.49
	8062308	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.25	CHEMBL5754	Homo sapiens	Inhibition	%	1.25
	8062694	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	3.35	CHEMBL5754	Homo sapiens	Inhibition	%	3.35
	8062792	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	2.78	CHEMBL5754	Homo sapiens	Inhibition	%	2.78
	8063016	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	0.74	CHEMBL5754	Homo sapiens	Inhibition	%	0.74
	8063148	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	2.57	CHEMBL5754	Homo sapiens	Inhibition	%	2.57
	8063315	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.48	CHEMBL5754	Homo sapiens	Inhibition	%	0.48
	8063539	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.08	CHEMBL5754	Homo sapiens	Inhibition	%	0.08
	8063647	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.03	CHEMBL5754	Homo sapiens	Inhibition	%	1.03
	8064053	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.66	CHEMBL5754	Homo sapiens	Inhibition	%	0.66
	8064168	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	3.94	CHEMBL5754	Homo sapiens	Inhibition	%	3.94
	8064602	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	1.37	CHEMBL5754	Homo sapiens	Inhibition	%	1.37
	8064740	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.3	CHEMBL5754	Homo sapiens	Inhibition	%	2.3
	8065130	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	Inhibition	%	0.0
	8065246	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.93	CHEMBL5754	Homo sapiens	Inhibition	%	0.93
	8065470	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.25	CHEMBL5754	Homo sapiens	Inhibition	%	0.25
	8065645	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	1.99	CHEMBL5754	Homo sapiens	Inhibition	%	1.99
	8065760	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.81	CHEMBL5754	Homo sapiens	Inhibition	%	0.81
	8065984	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	3.87	CHEMBL5754	Homo sapiens	Inhibition	%	3.87
	8066194	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.74	CHEMBL5754	Homo sapiens	Inhibition	%	0.74
	8066330	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	19.39	CHEMBL5754	Homo sapiens	Inhibition	%	19.39
	8066554	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	3.44	CHEMBL5754	Homo sapiens	Inhibition	%	3.44
	8066720	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	-0.43	CHEMBL5754	Homo sapiens	Inhibition	%	-0.43
	8067068	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	1.17	CHEMBL5754	Homo sapiens	Inhibition	%	1.17
	8067243	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.2	CHEMBL5754	Homo sapiens	Inhibition	%	1.2
	8067588	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.11	CHEMBL5754	Homo sapiens	Inhibition	%	0.11
	8067798	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.5	CHEMBL5754	Homo sapiens	Inhibition	%	0.5
	8068157	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	22.06	CHEMBL5754	Homo sapiens	Inhibition	%	22.06
	8068321	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	-0.09	CHEMBL5754	Homo sapiens	Inhibition	%	-0.09
	8068670	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.11	CHEMBL5754	Homo sapiens	Inhibition	%	0.11
	8068844	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	1.06	CHEMBL5754	Homo sapiens	Inhibition	%	1.06
	8069193	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-0.34	CHEMBL5754	Homo sapiens	Inhibition	%	-0.34
	8069488	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	2.98	CHEMBL5754	Homo sapiens	Inhibition	%	2.98
	8069649	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	1.81	CHEMBL5754	Homo sapiens	Inhibition	%	1.81
	8069873	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	-0.63	CHEMBL5754	Homo sapiens	Inhibition	%	-0.63
	8069999	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8070171	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.4	CHEMBL5754	Homo sapiens	Inhibition	%	1.4
	8070395	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	1.07	CHEMBL5754	Homo sapiens	Inhibition	%	1.07
	8070520	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	-0.28	CHEMBL5754	Homo sapiens	Inhibition	%	-0.28
	8070818	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	26.76	CHEMBL5754	Homo sapiens	Inhibition	%	26.76
	8071199	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	-0.34	CHEMBL5754	Homo sapiens	Inhibition	%	-0.34
	8071325	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.19	CHEMBL5754	Homo sapiens	Inhibition	%	-0.19
	8071722	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	1.46	CHEMBL5754	Homo sapiens	Inhibition	%	1.46
	8071847	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.5	CHEMBL5754	Homo sapiens	Inhibition	%	0.5
	8072071	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.51	CHEMBL5754	Homo sapiens	Inhibition	%	-0.51
	8072161	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	1.07	CHEMBL5754	Homo sapiens	Inhibition	%	1.07
	8072385	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	2.15	CHEMBL5754	Homo sapiens	Inhibition	%	2.15
	8072542	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.19	CHEMBL5754	Homo sapiens	Inhibition	%	1.19
	8072667	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.68	CHEMBL5754	Homo sapiens	Inhibition	%	-0.68
	8072891	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.78	CHEMBL5754	Homo sapiens	Inhibition	%	-0.78
	8073058	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	2.43	CHEMBL5754	Homo sapiens	Inhibition	%	2.43
	8073407	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.37	CHEMBL5754	Homo sapiens	Inhibition	%	0.37
	8073526	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	1.51	CHEMBL5754	Homo sapiens	Inhibition	%	1.51
	8073750	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	7.46	CHEMBL5754	Homo sapiens	Inhibition	%	7.46
	8073983	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	3.5	CHEMBL5754	Homo sapiens	Inhibition	%	3.5
	8074135	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.89	CHEMBL5754	Homo sapiens	Inhibition	%	0.89
	8074489	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.92	CHEMBL5754	Homo sapiens	Inhibition	%	0.92
	8074646	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.54	CHEMBL5754	Homo sapiens	Inhibition	%	1.54
	8074997	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	0.47	CHEMBL5754	Homo sapiens	Inhibition	%	0.47
	8075332	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.52	CHEMBL5754	Homo sapiens	Inhibition	%	0.52
	8075569	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	7.13	CHEMBL5754	Homo sapiens	Inhibition	%	7.13
	8075710	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.26	CHEMBL5754	Homo sapiens	Inhibition	%	0.26
	8075934	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	1.44	CHEMBL5754	Homo sapiens	Inhibition	%	1.44
	8076076	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.65	CHEMBL5754	Homo sapiens	Inhibition	%	-0.65
	8076224	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.97	CHEMBL5754	Homo sapiens	Inhibition	%	1.97
	8076448	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.87	CHEMBL5754	Homo sapiens	Inhibition	%	0.87
	8076582	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.44	CHEMBL5754	Homo sapiens	Inhibition	%	1.44
	8076908	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	0.72	CHEMBL5754	Homo sapiens	Inhibition	%	0.72
	8077155	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	74.52	CHEMBL5754	Homo sapiens	Inhibition	%	74.52
	8077507	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.41	CHEMBL5754	Homo sapiens	Inhibition	%	0.41
	8077658	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	5.41	CHEMBL5754	Homo sapiens	Inhibition	%	5.41
	8078025	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.86	CHEMBL5754	Homo sapiens	Inhibition	%	0.86
	8078164	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	1.26	CHEMBL5754	Homo sapiens	Inhibition	%	1.26
	8078490	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	0.47	CHEMBL5754	Homo sapiens	Inhibition	%	0.47
	8078740	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	90.73	CHEMBL5754	Homo sapiens	Inhibition	%	90.73
	8079080	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.13	CHEMBL5754	Homo sapiens	Inhibition	%	1.13
	8079238	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.02	CHEMBL5754	Homo sapiens	Inhibition	%	1.02
	8079604	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.67	CHEMBL5754	Homo sapiens	Inhibition	%	0.67
	8079743	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	11.65	CHEMBL5754	Homo sapiens	Inhibition	%	11.65
	8079967	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	7.27	CHEMBL5754	Homo sapiens	Inhibition	%	7.27
	8080072	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	1.99	CHEMBL5754	Homo sapiens	Inhibition	%	1.99
	8080324	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	24.6	CHEMBL5754	Homo sapiens	Inhibition	%	24.6
	8080548	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	77.53	CHEMBL5754	Homo sapiens	Inhibition	%	77.53
	8080663	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.07	CHEMBL5754	Homo sapiens	Inhibition	%	0.07
	8080827	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	5.24	CHEMBL5754	Homo sapiens	Inhibition	%	5.24
	8081051	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-0.05	CHEMBL5754	Homo sapiens	Inhibition	%	-0.05
	8081186	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.47	CHEMBL5754	Homo sapiens	Inhibition	%	1.47
	8081554	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	42.59	CHEMBL5754	Homo sapiens	Inhibition	%	42.59
	8081657	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	2.36	CHEMBL5754	Homo sapiens	Inhibition	%	2.36
	8081881	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	17.3	CHEMBL5754	Homo sapiens	Inhibition	%	17.3
	8082133	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	2.83	CHEMBL5754	Homo sapiens	Inhibition	%	2.83
	8082246	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	-0.37	CHEMBL5754	Homo sapiens	Inhibition	%	-0.37
	8082643	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.67	CHEMBL5754	Homo sapiens	Inhibition	%	0.67
	8082766	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.84	CHEMBL5754	Homo sapiens	Inhibition	%	0.84
	8082990	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.72	CHEMBL5754	Homo sapiens	Inhibition	%	0.72
	8083146	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	3.39	CHEMBL5754	Homo sapiens	Inhibition	%	3.39
	8083469	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	1.87	CHEMBL5754	Homo sapiens	Inhibition	%	1.87
	8083723	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	10.83	CHEMBL5754	Homo sapiens	Inhibition	%	10.83
	8083833	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.14	CHEMBL5754	Homo sapiens	Inhibition	%	0.14
	8084057	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.48	CHEMBL5754	Homo sapiens	Inhibition	%	0.48
	8084242	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	11.44	CHEMBL5754	Homo sapiens	Inhibition	%	11.44
	8084584	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.14	CHEMBL5754	Homo sapiens	Inhibition	%	1.14
	8084745	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	14.6	CHEMBL5754	Homo sapiens	Inhibition	%	14.6
	8085067	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	3.42	CHEMBL5754	Homo sapiens	Inhibition	%	3.42
	8085323	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	1.11	CHEMBL5754	Homo sapiens	Inhibition	%	1.11
	8085655	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.39	CHEMBL5754	Homo sapiens	Inhibition	%	0.39
	8085844	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	51.95	CHEMBL5754	Homo sapiens	Inhibition	%	51.95
	8086183	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.04	CHEMBL5754	Homo sapiens	Inhibition	%	1.04
	8086345	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	2.14	CHEMBL5754	Homo sapiens	Inhibition	%	2.14
	8086569	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	4.18	CHEMBL5754	Homo sapiens	Inhibition	%	4.18
	8086668	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	1.33	CHEMBL5754	Homo sapiens	Inhibition	%	1.33
	8086879	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	1.49	CHEMBL5754	Homo sapiens	Inhibition	%	1.49
	8087103	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	3.08	CHEMBL5754	Homo sapiens	Inhibition	%	3.08
	8087261	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.46	CHEMBL5754	Homo sapiens	Inhibition	%	1.46
	8087599	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	2.98	CHEMBL5754	Homo sapiens	Inhibition	%	2.98
	8087737	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.52	CHEMBL5754	Homo sapiens	Inhibition	%	3.52
	8088103	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.48	CHEMBL5754	Homo sapiens	Inhibition	%	1.48
	8088251	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.69	CHEMBL5754	Homo sapiens	Inhibition	%	0.69
	8088475	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.98	CHEMBL5754	Homo sapiens	Inhibition	%	0.98
	8088603	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	2.88	CHEMBL5754	Homo sapiens	Inhibition	%	2.88
	8088920	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.84	CHEMBL5754	Homo sapiens	Inhibition	%	2.84
	8089048	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.13	CHEMBL5754	Homo sapiens	Inhibition	%	-0.13
	8089272	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	2.83	CHEMBL5754	Homo sapiens	Inhibition	%	2.83
	8089420	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.89	CHEMBL5754	Homo sapiens	Inhibition	%	1.89
	8089764	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	-1.13	CHEMBL5754	Homo sapiens	Inhibition	%	-1.13
	8089944	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.03	CHEMBL5754	Homo sapiens	Inhibition	%	-0.03
	8090333	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	2.06	CHEMBL5754	Homo sapiens	Inhibition	%	2.06
	8090500	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.2	CHEMBL5754	Homo sapiens	Inhibition	%	1.2
	8090863	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.65	CHEMBL5754	Homo sapiens	Inhibition	%	0.65
	8091068	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.33	CHEMBL5754	Homo sapiens	Inhibition	%	2.33
	8091429	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	3.18	CHEMBL5754	Homo sapiens	Inhibition	%	3.18
	8091584	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.23	CHEMBL5754	Homo sapiens	Inhibition	%	2.23
	8091924	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	4.33	CHEMBL5754	Homo sapiens	Inhibition	%	4.33
	8092061	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.68	CHEMBL5754	Homo sapiens	Inhibition	%	1.68
	8092285	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.42	CHEMBL5754	Homo sapiens	Inhibition	%	1.42
	8092436	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	1.63	CHEMBL5754	Homo sapiens	Inhibition	%	1.63
	8092808	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	0.59	CHEMBL5754	Homo sapiens	Inhibition	%	0.59
	8092937	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	7.69	CHEMBL5754	Homo sapiens	Inhibition	%	7.69
	8093249	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.24	CHEMBL5754	Homo sapiens	Inhibition	%	0.24
	8093613	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	1.28	CHEMBL5754	Homo sapiens	Inhibition	%	1.28
	8093752	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	19.97	CHEMBL5754	Homo sapiens	Inhibition	%	19.97
	8094096	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	0.41	CHEMBL5754	Homo sapiens	Inhibition	%	0.41
	8094276	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.35	CHEMBL5754	Homo sapiens	Inhibition	%	1.35
	8094500	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.35	CHEMBL5754	Homo sapiens	Inhibition	%	1.35
	8094675	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	4.23	CHEMBL5754	Homo sapiens	Inhibition	%	4.23
	8094831	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	2.72	CHEMBL5754	Homo sapiens	Inhibition	%	2.72
	8095055	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.75	CHEMBL5754	Homo sapiens	Inhibition	%	1.75
	8095195	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	1.56	CHEMBL5754	Homo sapiens	Inhibition	%	1.56
	8095398	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.3	CHEMBL5754	Homo sapiens	Inhibition	%	1.3
	8095763	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	13.68	CHEMBL5754	Homo sapiens	Inhibition	%	13.68
	8095911	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	1.05	CHEMBL5754	Homo sapiens	Inhibition	%	1.05
	8096135	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	3.55	CHEMBL5754	Homo sapiens	Inhibition	%	3.55
	8096252	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	3.47	CHEMBL5754	Homo sapiens	Inhibition	%	3.47
	8096615	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8096771	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	1.6	CHEMBL5754	Homo sapiens	Inhibition	%	1.6
	8097142	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.48	CHEMBL5754	Homo sapiens	Inhibition	%	1.48
	8097449	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	2.09	CHEMBL5754	Homo sapiens	Inhibition	%	2.09
	8097673	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.97	CHEMBL5754	Homo sapiens	Inhibition	%	1.97
	8097823	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	16.91	CHEMBL5754	Homo sapiens	Inhibition	%	16.91
	8097956	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-0.3	CHEMBL5754	Homo sapiens	Inhibition	%	-0.3
	8098180	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	1.97	CHEMBL5754	Homo sapiens	Inhibition	%	1.97
	8098300	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.15	CHEMBL5754	Homo sapiens	Inhibition	%	1.15
	8098704	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.96	CHEMBL5754	Homo sapiens	Inhibition	%	0.96
	8098889	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	37.76	CHEMBL5754	Homo sapiens	Inhibition	%	37.76
	8099257	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.07	CHEMBL5754	Homo sapiens	Inhibition	%	1.07
	8099399	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	3.0	CHEMBL5754	Homo sapiens	Inhibition	%	3.0
	8099593	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.81	CHEMBL5754	Homo sapiens	Inhibition	%	0.81
	8099817	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.11	CHEMBL5754	Homo sapiens	Inhibition	%	0.11
	8099964	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	2.42	CHEMBL5754	Homo sapiens	Inhibition	%	2.42
	8100334	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	4.35	CHEMBL5754	Homo sapiens	Inhibition	%	4.35
	8100450	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	2.99	CHEMBL5754	Homo sapiens	Inhibition	%	2.99
	8100674	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.3	CHEMBL5754	Homo sapiens	Inhibition	%	2.3
	8100814	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.1	CHEMBL5754	Homo sapiens	Inhibition	%	2.1
	8100974	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	1.72	CHEMBL5754	Homo sapiens	Inhibition	%	1.72
	8101198	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.64	CHEMBL5754	Homo sapiens	Inhibition	%	2.64
	8101340	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	2.46	CHEMBL5754	Homo sapiens	Inhibition	%	2.46
	8101525	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.49	CHEMBL5754	Homo sapiens	Inhibition	%	2.49
	8101749	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	2.42	CHEMBL5754	Homo sapiens	Inhibition	%	2.42
	8102002	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	7.5	CHEMBL5754	Homo sapiens	Inhibition	%	7.5
	8102157	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	1.34	CHEMBL5754	Homo sapiens	Inhibition	%	1.34
	8102512	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-1.02	CHEMBL5754	Homo sapiens	Inhibition	%	-1.02
	8102632	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	1.0	CHEMBL5754	Homo sapiens	Inhibition	%	1.0
	8102856	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	1.33	CHEMBL5754	Homo sapiens	Inhibition	%	1.33
	8103034	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.77	CHEMBL5754	Homo sapiens	Inhibition	%	1.77
	8103230	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	1.25	CHEMBL5754	Homo sapiens	Inhibition	%	1.25
	8103592	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	0.72	CHEMBL5754	Homo sapiens	Inhibition	%	0.72
	8103742	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.91	CHEMBL5754	Homo sapiens	Inhibition	%	2.91
	8103966	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	2.02	CHEMBL5754	Homo sapiens	Inhibition	%	2.02
	8104151	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.16	CHEMBL5754	Homo sapiens	Inhibition	%	-0.16
	8104299	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.11	CHEMBL5754	Homo sapiens	Inhibition	%	5.11
	8104523	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	6.41	CHEMBL5754	Homo sapiens	Inhibition	%	6.41
	8104669	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	26.09	CHEMBL5754	Homo sapiens	Inhibition	%	26.09
	8105007	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.46	CHEMBL5754	Homo sapiens	Inhibition	%	2.46
	8105147	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.37	CHEMBL5754	Homo sapiens	Inhibition	%	0.37
	8105537	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	2.31	CHEMBL5754	Homo sapiens	Inhibition	%	2.31
	8105675	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	13.44	CHEMBL5754	Homo sapiens	Inhibition	%	13.44
	8105899	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.86	CHEMBL5754	Homo sapiens	Inhibition	%	1.86
	8105955	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.9	CHEMBL5754	Homo sapiens	Inhibition	%	0.9
	8106344	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.09	CHEMBL5754	Homo sapiens	Inhibition	%	1.09
	8106500	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	11.78	CHEMBL5754	Homo sapiens	Inhibition	%	11.78
	8106724	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	3.8	CHEMBL5754	Homo sapiens	Inhibition	%	3.8
	8106853	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	0.8	CHEMBL5754	Homo sapiens	Inhibition	%	0.8
	8107198	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	2.66	CHEMBL5754	Homo sapiens	Inhibition	%	2.66
	8107370	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	2.12	CHEMBL5754	Homo sapiens	Inhibition	%	2.12
	8107571	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	18.37	CHEMBL5754	Homo sapiens	Inhibition	%	18.37
	8107795	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.51	CHEMBL5754	Homo sapiens	Inhibition	%	1.51
	8107930	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	3.28	CHEMBL5754	Homo sapiens	Inhibition	%	3.28
	8108312	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	3.13	CHEMBL5754	Homo sapiens	Inhibition	%	3.13
	8108487	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.01	CHEMBL5754	Homo sapiens	Inhibition	%	0.01
	8108858	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	23.89	CHEMBL5754	Homo sapiens	Inhibition	%	23.89
	8109000	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.36	CHEMBL5754	Homo sapiens	Inhibition	%	1.36
	8109338	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	2.67	CHEMBL5754	Homo sapiens	Inhibition	%	2.67
	8109468	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	1.32	CHEMBL5754	Homo sapiens	Inhibition	%	1.32
	8109692	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.7	CHEMBL5754	Homo sapiens	Inhibition	%	1.7
	8109863	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	5.68	CHEMBL5754	Homo sapiens	Inhibition	%	5.68
	8110219	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.56	CHEMBL5754	Homo sapiens	Inhibition	%	3.56
	8110274	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	0.69	CHEMBL5754	Homo sapiens	Inhibition	%	0.69
	8110498	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.51	CHEMBL5754	Homo sapiens	Inhibition	%	1.51
	8110664	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	2.72	CHEMBL5754	Homo sapiens	Inhibition	%	2.72
	8111046	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	6.19	CHEMBL5754	Homo sapiens	Inhibition	%	6.19
	8111169	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-0.22	CHEMBL5754	Homo sapiens	Inhibition	%	-0.22
	8111520	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	11.62	CHEMBL5754	Homo sapiens	Inhibition	%	11.62
	8111686	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.92	CHEMBL5754	Homo sapiens	Inhibition	%	1.92
	8111910	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	7.2	CHEMBL5754	Homo sapiens	Inhibition	%	7.2
	8112115	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	6.57	CHEMBL5754	Homo sapiens	Inhibition	%	6.57
	8112252	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.19	CHEMBL5754	Homo sapiens	Inhibition	%	-0.19
	8112644	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.07	CHEMBL5754	Homo sapiens	Inhibition	%	3.07
	8112816	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.56	CHEMBL5754	Homo sapiens	Inhibition	%	-0.56
	8113192	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	2.05	CHEMBL5754	Homo sapiens	Inhibition	%	2.05
	8113328	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	3.69	CHEMBL5754	Homo sapiens	Inhibition	%	3.69
	8113552	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.94	CHEMBL5754	Homo sapiens	Inhibition	%	0.94
	8113676	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	4.11	CHEMBL5754	Homo sapiens	Inhibition	%	4.11
	8114016	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	1.06	CHEMBL5754	Homo sapiens	Inhibition	%	1.06
	8114192	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	1.47	CHEMBL5754	Homo sapiens	Inhibition	%	1.47
	8114548	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	2.34	CHEMBL5754	Homo sapiens	Inhibition	%	2.34
	8114824	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	1.5	CHEMBL5754	Homo sapiens	Inhibition	%	1.5
	8114990	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	0.43	CHEMBL5754	Homo sapiens	Inhibition	%	0.43
	8115379	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.52	CHEMBL5754	Homo sapiens	Inhibition	%	0.52
	8115499	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-1.15	CHEMBL5754	Homo sapiens	Inhibition	%	-1.15
	8115723	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	-0.14	CHEMBL5754	Homo sapiens	Inhibition	%	-0.14
	8115856	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	55.16	CHEMBL5754	Homo sapiens	Inhibition	%	55.16
	8116239	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	42.56	CHEMBL5754	Homo sapiens	Inhibition	%	42.56
	8116442	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	13.98	CHEMBL5754	Homo sapiens	Inhibition	%	13.98
	8116576	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.43	CHEMBL5754	Homo sapiens	Inhibition	%	-0.43
	8116800	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	-0.86	CHEMBL5754	Homo sapiens	Inhibition	%	-0.86
	8116972	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	5.58	CHEMBL5754	Homo sapiens	Inhibition	%	5.58
	8117143	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	-0.4	CHEMBL5754	Homo sapiens	Inhibition	%	-0.4
	8117367	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	2.47	CHEMBL5754	Homo sapiens	Inhibition	%	2.47
	8117525	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	7.52	CHEMBL5754	Homo sapiens	Inhibition	%	7.52
	8117879	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.91	CHEMBL5754	Homo sapiens	Inhibition	%	1.91
	8118017	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	3.57	CHEMBL5754	Homo sapiens	Inhibition	%	3.57
	8118357	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	0.45	CHEMBL5754	Homo sapiens	Inhibition	%	0.45
	8118529	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	2.54	CHEMBL5754	Homo sapiens	Inhibition	%	2.54
	8118753	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	1.49	CHEMBL5754	Homo sapiens	Inhibition	%	1.49
	8118889	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	3.94	CHEMBL5754	Homo sapiens	Inhibition	%	3.94
	8119160	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	-0.67	CHEMBL5754	Homo sapiens	Inhibition	%	-0.67
	8119319	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	2.95	CHEMBL5754	Homo sapiens	Inhibition	%	2.95
	8119543	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.61	CHEMBL5754	Homo sapiens	Inhibition	%	1.61
	8119710	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	0.84	CHEMBL5754	Homo sapiens	Inhibition	%	0.84
	8120053	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.31	CHEMBL5754	Homo sapiens	Inhibition	%	0.31
	8120192	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.96	CHEMBL5754	Homo sapiens	Inhibition	%	1.96
	8120576	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	0.43	CHEMBL5754	Homo sapiens	Inhibition	%	0.43
	8120777	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	62.08	CHEMBL5754	Homo sapiens	Inhibition	%	62.08
	8121129	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.13	CHEMBL5754	Homo sapiens	Inhibition	%	0.13
	8121301	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.7	CHEMBL5754	Homo sapiens	Inhibition	%	1.7
	8121692	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	4.28	CHEMBL5754	Homo sapiens	Inhibition	%	4.28
	8121855	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.43	CHEMBL5754	Homo sapiens	Inhibition	%	1.43
	8122200	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.7	CHEMBL5754	Homo sapiens	Inhibition	%	1.7
	8122338	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	4.5	CHEMBL5754	Homo sapiens	Inhibition	%	4.5
	8122562	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	11.01	CHEMBL5754	Homo sapiens	Inhibition	%	11.01
	8122682	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.37	CHEMBL5754	Homo sapiens	Inhibition	%	1.37
	8123073	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	2.54	CHEMBL5754	Homo sapiens	Inhibition	%	2.54
	8123215	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	5.05	CHEMBL5754	Homo sapiens	Inhibition	%	5.05
	8123493	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	0.75	CHEMBL5754	Homo sapiens	Inhibition	%	0.75
	8123867	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	11.32	CHEMBL5754	Homo sapiens	Inhibition	%	11.32
	8124034	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.84	CHEMBL5754	Homo sapiens	Inhibition	%	0.84
	8124377	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	0.65	CHEMBL5754	Homo sapiens	Inhibition	%	0.65
	8124516	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	3.07	CHEMBL5754	Homo sapiens	Inhibition	%	3.07
	8124740	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	2.11	CHEMBL5754	Homo sapiens	Inhibition	%	2.11
	8124905	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	2.44	CHEMBL5754	Homo sapiens	Inhibition	%	2.44
	8125106	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.89	CHEMBL5754	Homo sapiens	Inhibition	%	2.89
	8125330	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	4.67	CHEMBL5754	Homo sapiens	Inhibition	%	4.67
	8125460	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.54	CHEMBL5754	Homo sapiens	Inhibition	%	0.54
	8125628	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.44	CHEMBL5754	Homo sapiens	Inhibition	%	0.44
	8125852	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	1.01	CHEMBL5754	Homo sapiens	Inhibition	%	1.01
	8126016	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.44	CHEMBL5754	Homo sapiens	Inhibition	%	0.44
	8126180	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	5.23	CHEMBL5754	Homo sapiens	Inhibition	%	5.23
	8126404	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	4.42	CHEMBL5754	Homo sapiens	Inhibition	%	4.42
	8126519	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	1.13	CHEMBL5754	Homo sapiens	Inhibition	%	1.13
	8126879	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	46.34	CHEMBL5754	Homo sapiens	Inhibition	%	46.34
	8127001	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	0.75	CHEMBL5754	Homo sapiens	Inhibition	%	0.75
	8127225	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	2.59	CHEMBL5754	Homo sapiens	Inhibition	%	2.59
	8127392	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.11	CHEMBL5754	Homo sapiens	Inhibition	%	2.11
	8127534	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	18.37	CHEMBL5754	Homo sapiens	Inhibition	%	18.37
	8127758	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	2.8	CHEMBL5754	Homo sapiens	Inhibition	%	2.8
	8127822	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.25	CHEMBL5754	Homo sapiens	Inhibition	%	1.25
	8128046	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	3.17	CHEMBL5754	Homo sapiens	Inhibition	%	3.17
	8128198	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.25	CHEMBL5754	Homo sapiens	Inhibition	%	1.25
	8128365	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	4.83	CHEMBL5754	Homo sapiens	Inhibition	%	4.83
	8128589	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	-0.44	CHEMBL5754	Homo sapiens	Inhibition	%	-0.44
	8128708	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	17.26	CHEMBL5754	Homo sapiens	Inhibition	%	17.26
	8129069	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	6.06	CHEMBL5754	Homo sapiens	Inhibition	%	6.06
	8129240	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-0.26	CHEMBL5754	Homo sapiens	Inhibition	%	-0.26
	8129653	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.48	CHEMBL5754	Homo sapiens	Inhibition	%	2.48
	8129792	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.56	CHEMBL5754	Homo sapiens	Inhibition	%	0.56
	8130177	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.89	CHEMBL5754	Homo sapiens	Inhibition	%	0.89
	8130349	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	2.52	CHEMBL5754	Homo sapiens	Inhibition	%	2.52
	8130733	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	18.94	CHEMBL5754	Homo sapiens	Inhibition	%	18.94
	8130849	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.08	CHEMBL5754	Homo sapiens	Inhibition	%	2.08
	8131212	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.03	CHEMBL5754	Homo sapiens	Inhibition	%	3.03
	8131556	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.08	CHEMBL5754	Homo sapiens	Inhibition	%	2.08
	8131723	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.65	CHEMBL5754	Homo sapiens	Inhibition	%	2.65
	8132088	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	4.23	CHEMBL5754	Homo sapiens	Inhibition	%	4.23
	8132374	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.12	CHEMBL5754	Homo sapiens	Inhibition	%	1.12
	8132521	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.49	CHEMBL5754	Homo sapiens	Inhibition	%	2.49
	8132913	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	2.25	CHEMBL5754	Homo sapiens	Inhibition	%	2.25
	8133034	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-0.78	CHEMBL5754	Homo sapiens	Inhibition	%	-0.78
	8133258	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	-0.74	CHEMBL5754	Homo sapiens	Inhibition	%	-0.74
	8133396	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.32	CHEMBL5754	Homo sapiens	Inhibition	%	2.32
	8133568	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.68	CHEMBL5754	Homo sapiens	Inhibition	%	0.68
	8133792	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.13	CHEMBL5754	Homo sapiens	Inhibition	%	1.13
	8133972	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	17.11	CHEMBL5754	Homo sapiens	Inhibition	%	17.11
	8134120	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	0.16	CHEMBL5754	Homo sapiens	Inhibition	%	0.16
	8134344	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.62	CHEMBL5754	Homo sapiens	Inhibition	%	1.62
	8134504	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.31	CHEMBL5754	Homo sapiens	Inhibition	%	0.31
	8134688	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	3.29	CHEMBL5754	Homo sapiens	Inhibition	%	3.29
	8135072	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.52	CHEMBL5754	Homo sapiens	Inhibition	%	2.52
	8135187	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	2.71	CHEMBL5754	Homo sapiens	Inhibition	%	2.71
	8135411	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	2.86	CHEMBL5754	Homo sapiens	Inhibition	%	2.86
	8135552	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	6.36	CHEMBL5754	Homo sapiens	Inhibition	%	6.36
	8135897	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	1.09	CHEMBL5754	Homo sapiens	Inhibition	%	1.09
	8136065	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	0.94	CHEMBL5754	Homo sapiens	Inhibition	%	0.94
	8136433	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	2.61	CHEMBL5754	Homo sapiens	Inhibition	%	2.61
	8136723	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	1.75	CHEMBL5754	Homo sapiens	Inhibition	%	1.75
	8136858	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	-0.78	CHEMBL5754	Homo sapiens	Inhibition	%	-0.78
	8137082	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	3.04	CHEMBL5754	Homo sapiens	Inhibition	%	3.04
	8137245	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	0.58	CHEMBL5754	Homo sapiens	Inhibition	%	0.58
	8137589	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	-0.27	CHEMBL5754	Homo sapiens	Inhibition	%	-0.27
	8137737	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.11	CHEMBL5754	Homo sapiens	Inhibition	%	2.11
	8138127	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	3.48	CHEMBL5754	Homo sapiens	Inhibition	%	3.48
	8138306	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.17	CHEMBL5754	Homo sapiens	Inhibition	%	-0.17
	8138678	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	1.15	CHEMBL5754	Homo sapiens	Inhibition	%	1.15
	8138836	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.19	CHEMBL5754	Homo sapiens	Inhibition	%	0.19
	8139021	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	18.9	CHEMBL5754	Homo sapiens	Inhibition	%	18.9
	8139245	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	1.14	CHEMBL5754	Homo sapiens	Inhibition	%	1.14
	8139404	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	3.91	CHEMBL5754	Homo sapiens	Inhibition	%	3.91
	8139742	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	3.74	CHEMBL5754	Homo sapiens	Inhibition	%	3.74
	8139883	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.49	CHEMBL5754	Homo sapiens	Inhibition	%	3.49
	8140107	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	3.99	CHEMBL5754	Homo sapiens	Inhibition	%	3.99
	8140230	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.12	CHEMBL5754	Homo sapiens	Inhibition	%	2.12
	8140389	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	0.58	CHEMBL5754	Homo sapiens	Inhibition	%	0.58
	8140613	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.61	CHEMBL5754	Homo sapiens	Inhibition	%	0.61
	8140756	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	3.33	CHEMBL5754	Homo sapiens	Inhibition	%	3.33
	8141058	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.37	CHEMBL5754	Homo sapiens	Inhibition	%	0.37
	8141412	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.31	CHEMBL5754	Homo sapiens	Inhibition	%	0.31
	8141572	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	9.44	CHEMBL5754	Homo sapiens	Inhibition	%	9.44
	8141915	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.46	CHEMBL5754	Homo sapiens	Inhibition	%	1.46
	8142076	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	1.34	CHEMBL5754	Homo sapiens	Inhibition	%	1.34
	8142300	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	0.93	CHEMBL5754	Homo sapiens	Inhibition	%	0.93
	8142468	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	8.72	CHEMBL5754	Homo sapiens	Inhibition	%	8.72
	8142644	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.58	CHEMBL5754	Homo sapiens	Inhibition	%	1.58
	8143017	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.5	CHEMBL5754	Homo sapiens	Inhibition	%	0.5
	8143172	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.36	CHEMBL5754	Homo sapiens	Inhibition	%	2.36
	8143396	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.95	CHEMBL5754	Homo sapiens	Inhibition	%	1.95
	8143583	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	2.32	CHEMBL5754	Homo sapiens	Inhibition	%	2.32
	8143742	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	2.61	CHEMBL5754	Homo sapiens	Inhibition	%	2.61
	8144080	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	2.98	CHEMBL5754	Homo sapiens	Inhibition	%	2.98
	8144443	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.46	CHEMBL5754	Homo sapiens	Inhibition	%	1.46
	8144573	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	2.33	CHEMBL5754	Homo sapiens	Inhibition	%	2.33
	8144950	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.19	CHEMBL5754	Homo sapiens	Inhibition	%	1.19
	8145087	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	3.85	CHEMBL5754	Homo sapiens	Inhibition	%	3.85
	8145311	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.5	CHEMBL5754	Homo sapiens	Inhibition	%	2.5
	8145400	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.93	CHEMBL5754	Homo sapiens	Inhibition	%	1.93
	8145748	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.56	CHEMBL5754	Homo sapiens	Inhibition	%	0.56
	8145909	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	2.82	CHEMBL5754	Homo sapiens	Inhibition	%	2.82
	8146133	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	12.76	CHEMBL5754	Homo sapiens	Inhibition	%	12.76
	8146253	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-1.27	CHEMBL5754	Homo sapiens	Inhibition	%	-1.27
	8146637	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.47	CHEMBL5754	Homo sapiens	Inhibition	%	0.47
	8146804	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	49.89	CHEMBL5754	Homo sapiens	Inhibition	%	49.89
	8146973	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	-0.03	CHEMBL5754	Homo sapiens	Inhibition	%	-0.03
	8147197	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.65	CHEMBL5754	Homo sapiens	Inhibition	%	0.65
	8147339	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.13	CHEMBL5754	Homo sapiens	Inhibition	%	1.13
	8147716	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8147903	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.93	CHEMBL5754	Homo sapiens	Inhibition	%	0.93
	8148061	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	2.82	CHEMBL5754	Homo sapiens	Inhibition	%	2.82
	8148285	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	2.77	CHEMBL5754	Homo sapiens	Inhibition	%	2.77
	8148399	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	2.37	CHEMBL5754	Homo sapiens	Inhibition	%	2.37
	8148762	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	3.82	CHEMBL5754	Homo sapiens	Inhibition	%	3.82
	8148900	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.51	CHEMBL5754	Homo sapiens	Inhibition	%	1.51
	8149124	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	2.24	CHEMBL5754	Homo sapiens	Inhibition	%	2.24
	8149283	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.8	CHEMBL5754	Homo sapiens	Inhibition	%	0.8
	8149641	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.2	CHEMBL5754	Homo sapiens	Inhibition	%	2.2
	8149739	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.21	CHEMBL5754	Homo sapiens	Inhibition	%	0.21
	8149963	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.46	CHEMBL5754	Homo sapiens	Inhibition	%	0.46
	8150088	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.1	CHEMBL5754	Homo sapiens	Inhibition	%	0.1
	8150472	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.97	CHEMBL5754	Homo sapiens	Inhibition	%	-0.97
	8150592	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	-0.2	CHEMBL5754	Homo sapiens	Inhibition	%	-0.2
	8150981	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.65	CHEMBL5754	Homo sapiens	Inhibition	%	0.65
	8151144	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	1.68	CHEMBL5754	Homo sapiens	Inhibition	%	1.68
	8151545	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.15	CHEMBL5754	Homo sapiens	Inhibition	%	2.15
	8151683	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.01	CHEMBL5754	Homo sapiens	Inhibition	%	1.01
	8152061	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.74	CHEMBL5754	Homo sapiens	Inhibition	%	1.74
	8152249	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	5.08	CHEMBL5754	Homo sapiens	Inhibition	%	5.08
	8152631	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	4.32	CHEMBL5754	Homo sapiens	Inhibition	%	4.32
	8152745	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.78	CHEMBL5754	Homo sapiens	Inhibition	%	2.78
	8152969	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	3.51	CHEMBL5754	Homo sapiens	Inhibition	%	3.51
	8153108	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.62	CHEMBL5754	Homo sapiens	Inhibition	%	1.62
	8153469	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.3	CHEMBL5754	Homo sapiens	Inhibition	%	2.3
	8153626	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-0.12	CHEMBL5754	Homo sapiens	Inhibition	%	-0.12
	8153983	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	7.71	CHEMBL5754	Homo sapiens	Inhibition	%	7.71
	8154304	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.04	CHEMBL5754	Homo sapiens	Inhibition	%	1.04
	8154430	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	2.11	CHEMBL5754	Homo sapiens	Inhibition	%	2.11
	8154813	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.31	CHEMBL5754	Homo sapiens	Inhibition	%	0.31
	8154933	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.63	CHEMBL5754	Homo sapiens	Inhibition	%	-0.63
	8155157	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-1.03	CHEMBL5754	Homo sapiens	Inhibition	%	-1.03
	8155333	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.15	CHEMBL5754	Homo sapiens	Inhibition	%	-0.15
	8155494	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	3.83	CHEMBL5754	Homo sapiens	Inhibition	%	3.83
	8155718	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	0.59	CHEMBL5754	Homo sapiens	Inhibition	%	0.59
	8155896	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.34	CHEMBL5754	Homo sapiens	Inhibition	%	2.34
	8156034	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.1	CHEMBL5754	Homo sapiens	Inhibition	%	1.1
	8156258	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	1.8	CHEMBL5754	Homo sapiens	Inhibition	%	1.8
	8156470	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.77	CHEMBL5754	Homo sapiens	Inhibition	%	1.77
	8156620	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.52	CHEMBL5754	Homo sapiens	Inhibition	%	1.52
	8156844	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.24	CHEMBL5754	Homo sapiens	Inhibition	%	1.24
	8156987	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	10.86	CHEMBL5754	Homo sapiens	Inhibition	%	10.86
	8157331	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	3.18	CHEMBL5754	Homo sapiens	Inhibition	%	3.18
	8157472	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	1.28	CHEMBL5754	Homo sapiens	Inhibition	%	1.28
	8157826	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	2.24	CHEMBL5754	Homo sapiens	Inhibition	%	2.24
	8157987	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	1.47	CHEMBL5754	Homo sapiens	Inhibition	%	1.47
	8158211	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	1.5	CHEMBL5754	Homo sapiens	Inhibition	%	1.5
	8158237	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	1.32	CHEMBL5754	Homo sapiens	Inhibition	%	1.32
	8158461	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	2.19	CHEMBL5754	Homo sapiens	Inhibition	%	2.19
	8158619	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	5.97	CHEMBL5754	Homo sapiens	Inhibition	%	5.97
	8158788	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.5	CHEMBL5754	Homo sapiens	Inhibition	%	2.5
	8159012	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	5.44	CHEMBL5754	Homo sapiens	Inhibition	%	5.44
	8159147	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	1.79	CHEMBL5754	Homo sapiens	Inhibition	%	1.79
	8159491	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	1.3	CHEMBL5754	Homo sapiens	Inhibition	%	1.3
	8159622	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	9.85	CHEMBL5754	Homo sapiens	Inhibition	%	9.85
	8159846	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	7.3	CHEMBL5754	Homo sapiens	Inhibition	%	7.3
	8159987	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	2.7	CHEMBL5754	Homo sapiens	Inhibition	%	2.7
	8160348	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8160498	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.43	CHEMBL5754	Homo sapiens	Inhibition	%	0.43
	8160792	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	3.33	CHEMBL5754	Homo sapiens	Inhibition	%	3.33
	8161166	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	5.47	CHEMBL5754	Homo sapiens	Inhibition	%	5.47
	8161309	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	3.11	CHEMBL5754	Homo sapiens	Inhibition	%	3.11
	8161658	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.9	CHEMBL5754	Homo sapiens	Inhibition	%	0.9
	8161796	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	7.81	CHEMBL5754	Homo sapiens	Inhibition	%	7.81
	8162020	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	3.62	CHEMBL5754	Homo sapiens	Inhibition	%	3.62
	8162150	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	13.19	CHEMBL5754	Homo sapiens	Inhibition	%	13.19
	8162534	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.34	CHEMBL5754	Homo sapiens	Inhibition	%	2.34
	8162787	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	4.51	CHEMBL5754	Homo sapiens	Inhibition	%	4.51
	8162935	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	20.97	CHEMBL5754	Homo sapiens	Inhibition	%	20.97
	8163328	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	2.49	CHEMBL5754	Homo sapiens	Inhibition	%	2.49
	8163462	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	0.94	CHEMBL5754	Homo sapiens	Inhibition	%	0.94
	8163686	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	2.45	CHEMBL5754	Homo sapiens	Inhibition	%	2.45
	8163809	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.25	CHEMBL5754	Homo sapiens	Inhibition	%	2.25
	8164167	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	40.74	CHEMBL5754	Homo sapiens	Inhibition	%	40.74
	8164307	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.1	CHEMBL5754	Homo sapiens	Inhibition	%	1.1
	8164686	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	1.74	CHEMBL5754	Homo sapiens	Inhibition	%	1.74
	8164830	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.28	CHEMBL5754	Homo sapiens	Inhibition	%	1.28
	8165054	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.19	CHEMBL5754	Homo sapiens	Inhibition	%	2.19
	8165124	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	2.04	CHEMBL5754	Homo sapiens	Inhibition	%	2.04
	8165489	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	0.15	CHEMBL5754	Homo sapiens	Inhibition	%	0.15
	8165632	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	16.42	CHEMBL5754	Homo sapiens	Inhibition	%	16.42
	8165856	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.32	CHEMBL5754	Homo sapiens	Inhibition	%	1.32
	8165982	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	8.27	CHEMBL5754	Homo sapiens	Inhibition	%	8.27
	8166344	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	20.18	CHEMBL5754	Homo sapiens	Inhibition	%	20.18
	8166474	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.16	CHEMBL5754	Homo sapiens	Inhibition	%	1.16
	8166799	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	8.0	CHEMBL5754	Homo sapiens	Inhibition	%	8.0
	8167111	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8167252	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	58.71	CHEMBL5754	Homo sapiens	Inhibition	%	58.71
	8167476	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	4.25	CHEMBL5754	Homo sapiens	Inhibition	%	4.25
	8167640	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.96	CHEMBL5754	Homo sapiens	Inhibition	%	1.96
	8167997	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.33	CHEMBL5754	Homo sapiens	Inhibition	%	1.33
	8168121	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.77	CHEMBL5754	Homo sapiens	Inhibition	%	0.77
	8168486	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	1.93	CHEMBL5754	Homo sapiens	Inhibition	%	1.93
	8168622	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.23	CHEMBL5754	Homo sapiens	Inhibition	%	1.23
	8168846	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	1.62	CHEMBL5754	Homo sapiens	Inhibition	%	1.62
	8169010	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	9.89	CHEMBL5754	Homo sapiens	Inhibition	%	9.89
	8169376	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.82	CHEMBL5754	Homo sapiens	Inhibition	%	2.82
	8169456	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	4.01	CHEMBL5754	Homo sapiens	Inhibition	%	4.01
	8169680	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	11.76	CHEMBL5754	Homo sapiens	Inhibition	%	11.76
	8169814	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	1.48	CHEMBL5754	Homo sapiens	Inhibition	%	1.48
	8170183	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.47	CHEMBL5754	Homo sapiens	Inhibition	%	1.47
	8170308	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.25	CHEMBL5754	Homo sapiens	Inhibition	%	1.25
	8170672	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	10.54	CHEMBL5754	Homo sapiens	Inhibition	%	10.54
	8170807	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.71	CHEMBL5754	Homo sapiens	Inhibition	%	2.71
	8171031	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.24	CHEMBL5754	Homo sapiens	Inhibition	%	0.24
	8171228	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	1.78	CHEMBL5754	Homo sapiens	Inhibition	%	1.78
	8171445	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	4.43	CHEMBL5754	Homo sapiens	Inhibition	%	4.43
	8171810	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	6.44	CHEMBL5754	Homo sapiens	Inhibition	%	6.44
	8171963	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.82	CHEMBL5754	Homo sapiens	Inhibition	%	1.82
	8172319	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.86	CHEMBL5754	Homo sapiens	Inhibition	%	4.86
	8172447	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	4.62	CHEMBL5754	Homo sapiens	Inhibition	%	4.62
	8172671	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.49	CHEMBL5754	Homo sapiens	Inhibition	%	1.49
	8172813	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	2.67	CHEMBL5754	Homo sapiens	Inhibition	%	2.67
	8173173	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	6.55	CHEMBL5754	Homo sapiens	Inhibition	%	6.55
	8173338	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	1.15	CHEMBL5754	Homo sapiens	Inhibition	%	1.15
	8173703	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.85	CHEMBL5754	Homo sapiens	Inhibition	%	1.85
	8174014	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	56.26	CHEMBL5754	Homo sapiens	Inhibition	%	56.26
	8174146	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.01	CHEMBL5754	Homo sapiens	Inhibition	%	0.01
	8174518	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.89	CHEMBL5754	Homo sapiens	Inhibition	%	0.89
	8174640	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	2.15	CHEMBL5754	Homo sapiens	Inhibition	%	2.15
	8174864	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.88	CHEMBL5754	Homo sapiens	Inhibition	%	0.88
	8175007	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	54.46	CHEMBL5754	Homo sapiens	Inhibition	%	54.46
	8175367	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	2.61	CHEMBL5754	Homo sapiens	Inhibition	%	2.61
	8175623	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	17.89	CHEMBL5754	Homo sapiens	Inhibition	%	17.89
	8175786	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.36	CHEMBL5754	Homo sapiens	Inhibition	%	1.36
	8176010	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	0.82	CHEMBL5754	Homo sapiens	Inhibition	%	0.82
	8176163	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	4.49	CHEMBL5754	Homo sapiens	Inhibition	%	4.49
	8176312	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	5.56	CHEMBL5754	Homo sapiens	Inhibition	%	5.56
	8176536	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	6.9	CHEMBL5754	Homo sapiens	Inhibition	%	6.9
	8176668	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	27.09	CHEMBL5754	Homo sapiens	Inhibition	%	27.09
	8177022	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	3.83	CHEMBL5754	Homo sapiens	Inhibition	%	3.83
	8177164	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.37	CHEMBL5754	Homo sapiens	Inhibition	%	2.37
	8177526	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	3.93	CHEMBL5754	Homo sapiens	Inhibition	%	3.93
	8177690	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	5.01	CHEMBL5754	Homo sapiens	Inhibition	%	5.01
	8177914	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.07	CHEMBL5754	Homo sapiens	Inhibition	%	2.07
	8178054	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.53	CHEMBL5754	Homo sapiens	Inhibition	%	3.53
	8178366	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.04	CHEMBL5754	Homo sapiens	Inhibition	%	1.04
	8178493	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	0.82	CHEMBL5754	Homo sapiens	Inhibition	%	0.82
	8178717	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.23	CHEMBL5754	Homo sapiens	Inhibition	%	1.23
	8178866	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.47	CHEMBL5754	Homo sapiens	Inhibition	%	0.47
	8179213	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.97	CHEMBL5754	Homo sapiens	Inhibition	%	1.97
	8179357	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	4.76	CHEMBL5754	Homo sapiens	Inhibition	%	4.76
	8179581	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	33.66	CHEMBL5754	Homo sapiens	Inhibition	%	33.66
	8179718	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.58	CHEMBL5754	Homo sapiens	Inhibition	%	0.58
	8179975	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	2.21	CHEMBL5754	Homo sapiens	Inhibition	%	2.21
	8180353	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.49	CHEMBL5754	Homo sapiens	Inhibition	%	1.49
	8180509	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	13.3	CHEMBL5754	Homo sapiens	Inhibition	%	13.3
	8180881	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	32.45	CHEMBL5754	Homo sapiens	Inhibition	%	32.45
	8181014	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	2.23	CHEMBL5754	Homo sapiens	Inhibition	%	2.23
	8181369	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	4.34	CHEMBL5754	Homo sapiens	Inhibition	%	4.34
	8181509	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	3.69	CHEMBL5754	Homo sapiens	Inhibition	%	3.69
	8181733	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	2.2	CHEMBL5754	Homo sapiens	Inhibition	%	2.2
	8181872	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	15.88	CHEMBL5754	Homo sapiens	Inhibition	%	15.88
	8182259	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	2.43	CHEMBL5754	Homo sapiens	Inhibition	%	2.43
	8182399	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.29	CHEMBL5754	Homo sapiens	Inhibition	%	1.29
	8182715	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.72	CHEMBL5754	Homo sapiens	Inhibition	%	1.72
	8183061	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	2.4	CHEMBL5754	Homo sapiens	Inhibition	%	2.4
	8183210	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	0.15	CHEMBL5754	Homo sapiens	Inhibition	%	0.15
	8183434	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	1.64	CHEMBL5754	Homo sapiens	Inhibition	%	1.64
	8183563	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	4.98	CHEMBL5754	Homo sapiens	Inhibition	%	4.98
	8183929	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	2.09	CHEMBL5754	Homo sapiens	Inhibition	%	2.09
	8184065	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	-0.36	CHEMBL5754	Homo sapiens	Inhibition	%	-0.36
	8184331	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	3.02	CHEMBL5754	Homo sapiens	Inhibition	%	3.02
	8184702	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.57	CHEMBL5754	Homo sapiens	Inhibition	%	1.57
	8184859	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.21	CHEMBL5754	Homo sapiens	Inhibition	%	2.21
	8185083	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.65	CHEMBL5754	Homo sapiens	Inhibition	%	2.65
	8185232	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	2.33	CHEMBL5754	Homo sapiens	Inhibition	%	2.33
	8185363	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	1.71	CHEMBL5754	Homo sapiens	Inhibition	%	1.71
	8185587	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	2.28	CHEMBL5754	Homo sapiens	Inhibition	%	2.28
	8185718	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	28.16	CHEMBL5754	Homo sapiens	Inhibition	%	28.16
	8186081	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	5.77	CHEMBL5754	Homo sapiens	Inhibition	%	5.77
	8186222	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.45	CHEMBL5754	Homo sapiens	Inhibition	%	1.45
	8186446	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.84	CHEMBL5754	Homo sapiens	Inhibition	%	1.84
	8186610	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.18	CHEMBL5754	Homo sapiens	Inhibition	%	1.18
	8186749	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.56	CHEMBL5754	Homo sapiens	Inhibition	%	2.56
	8186973	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	1.9	CHEMBL5754	Homo sapiens	Inhibition	%	1.9
	8187071	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	0.98	CHEMBL5754	Homo sapiens	Inhibition	%	0.98
	8187419	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.08	CHEMBL5754	Homo sapiens	Inhibition	%	1.08
	8187791	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	0.15	CHEMBL5754	Homo sapiens	Inhibition	%	0.15
	8187920	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	6.4	CHEMBL5754	Homo sapiens	Inhibition	%	6.4
	8188287	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	11.18	CHEMBL5754	Homo sapiens	Inhibition	%	11.18
	8188422	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.03	CHEMBL5754	Homo sapiens	Inhibition	%	1.03
	8188646	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	3.52	CHEMBL5754	Homo sapiens	Inhibition	%	3.52
	8188696	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.87	CHEMBL5754	Homo sapiens	Inhibition	%	1.87
	8188920	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.32	CHEMBL5754	Homo sapiens	Inhibition	%	3.32
	8189068	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.37	CHEMBL5754	Homo sapiens	Inhibition	%	0.37
	8189448	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	4.17	CHEMBL5754	Homo sapiens	Inhibition	%	4.17
	8189597	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	3.13	CHEMBL5754	Homo sapiens	Inhibition	%	3.13
	8189953	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	3.56	CHEMBL5754	Homo sapiens	Inhibition	%	3.56
	8190085	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	2.01	CHEMBL5754	Homo sapiens	Inhibition	%	2.01
	8190309	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	5.18	CHEMBL5754	Homo sapiens	Inhibition	%	5.18
	8190449	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.69	CHEMBL5754	Homo sapiens	Inhibition	%	2.69
	8190810	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	0.86	CHEMBL5754	Homo sapiens	Inhibition	%	0.86
	8190974	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.26	CHEMBL5754	Homo sapiens	Inhibition	%	2.26
	8191336	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	8.9	CHEMBL5754	Homo sapiens	Inhibition	%	8.9
	8191432	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.6	CHEMBL5754	Homo sapiens	Inhibition	%	1.6
	8191656	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	0.35	CHEMBL5754	Homo sapiens	Inhibition	%	0.35
	8191778	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	3.99	CHEMBL5754	Homo sapiens	Inhibition	%	3.99
	8192151	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.03	CHEMBL5754	Homo sapiens	Inhibition	%	1.03
	8192280	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	2.25	CHEMBL5754	Homo sapiens	Inhibition	%	2.25
	8192504	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	1.91	CHEMBL5754	Homo sapiens	Inhibition	%	1.91
	8192648	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.26	CHEMBL5754	Homo sapiens	Inhibition	%	1.26
	8193008	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	-0.72	CHEMBL5754	Homo sapiens	Inhibition	%	-0.72
	8193280	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	1.2	CHEMBL5754	Homo sapiens	Inhibition	%	1.2
	8193425	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	4.17	CHEMBL5754	Homo sapiens	Inhibition	%	4.17
	8193806	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	15.51	CHEMBL5754	Homo sapiens	Inhibition	%	15.51
	8193955	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	2.01	CHEMBL5754	Homo sapiens	Inhibition	%	2.01
	8194179	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	3.21	CHEMBL5754	Homo sapiens	Inhibition	%	3.21
	8194310	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.47	CHEMBL5754	Homo sapiens	Inhibition	%	1.47
	8194665	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.11	CHEMBL5754	Homo sapiens	Inhibition	%	3.11
	8194808	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.61	CHEMBL5754	Homo sapiens	Inhibition	%	1.61
	8195165	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	2.05	CHEMBL5754	Homo sapiens	Inhibition	%	2.05
	8195329	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.71	CHEMBL5754	Homo sapiens	Inhibition	%	1.71
	8195553	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	6.69	CHEMBL5754	Homo sapiens	Inhibition	%	6.69
	8195692	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.75	CHEMBL5754	Homo sapiens	Inhibition	%	1.75
	8196014	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.44	CHEMBL5754	Homo sapiens	Inhibition	%	2.44
	8196131	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	0.9	CHEMBL5754	Homo sapiens	Inhibition	%	0.9
	8196355	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	2.17	CHEMBL5754	Homo sapiens	Inhibition	%	2.17
	8196505	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.31	CHEMBL5754	Homo sapiens	Inhibition	%	1.31
	8196857	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	2.12	CHEMBL5754	Homo sapiens	Inhibition	%	2.12
	8196998	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	3.49	CHEMBL5754	Homo sapiens	Inhibition	%	3.49
	8197359	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	2.36	CHEMBL5754	Homo sapiens	Inhibition	%	2.36
	8197634	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	2.29	CHEMBL5754	Homo sapiens	Inhibition	%	2.29
	8197774	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	1.66	CHEMBL5754	Homo sapiens	Inhibition	%	1.66
	8197998	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	9.04	CHEMBL5754	Homo sapiens	Inhibition	%	9.04
	8198155	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	2.4	CHEMBL5754	Homo sapiens	Inhibition	%	2.4
	8198517	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.12	CHEMBL5754	Homo sapiens	Inhibition	%	1.12
	8198647	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	4.13	CHEMBL5754	Homo sapiens	Inhibition	%	4.13
	8199002	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	2.16	CHEMBL5754	Homo sapiens	Inhibition	%	2.16
	8199150	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	2.82	CHEMBL5754	Homo sapiens	Inhibition	%	2.82
	8199374	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.0	CHEMBL5754	Homo sapiens	Inhibition	%	3.0
	8199508	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	0.48	CHEMBL5754	Homo sapiens	Inhibition	%	0.48
	8199895	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.38	CHEMBL5754	Homo sapiens	Inhibition	%	0.38
	8200033	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.19	CHEMBL5754	Homo sapiens	Inhibition	%	2.19
	8200361	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.1	CHEMBL5754	Homo sapiens	Inhibition	%	0.1
	8200700	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.99	CHEMBL5754	Homo sapiens	Inhibition	%	1.99
	8200850	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.67	CHEMBL5754	Homo sapiens	Inhibition	%	1.67
	8201204	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	9.4	CHEMBL5754	Homo sapiens	Inhibition	%	9.4
	8201339	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.25	CHEMBL5754	Homo sapiens	Inhibition	%	0.25
	8201563	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	1.99	CHEMBL5754	Homo sapiens	Inhibition	%	1.99
	8201696	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.17	CHEMBL5754	Homo sapiens	Inhibition	%	-0.17
	8201975	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.59	CHEMBL5754	Homo sapiens	Inhibition	%	1.59
	8202339	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	0.78	CHEMBL5754	Homo sapiens	Inhibition	%	0.78
	8202506	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	3.63	CHEMBL5754	Homo sapiens	Inhibition	%	3.63
	8202855	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.84	CHEMBL5754	Homo sapiens	Inhibition	%	1.84
	8202985	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.04	CHEMBL5754	Homo sapiens	Inhibition	%	4.04
	8203209	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.27	CHEMBL5754	Homo sapiens	Inhibition	%	4.27
	8203340	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	2.63	CHEMBL5754	Homo sapiens	Inhibition	%	2.63
	8203710	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.05	CHEMBL5754	Homo sapiens	Inhibition	%	1.05
	8203844	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.07	CHEMBL5754	Homo sapiens	Inhibition	%	1.07
	8204068	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.2	CHEMBL5754	Homo sapiens	Inhibition	%	2.2
	8204234	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	0.19	CHEMBL5754	Homo sapiens	Inhibition	%	0.19
	8204371	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.1	CHEMBL5754	Homo sapiens	Inhibition	%	2.1
	8204595	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	3.98	CHEMBL5754	Homo sapiens	Inhibition	%	3.98
	8204700	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.26	CHEMBL5754	Homo sapiens	Inhibition	%	1.26
	8205039	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	15.43	CHEMBL5754	Homo sapiens	Inhibition	%	15.43
	8205188	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.01	CHEMBL5754	Homo sapiens	Inhibition	%	1.01
	8205412	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	5.05	CHEMBL5754	Homo sapiens	Inhibition	%	5.05
	8205548	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	1.03	CHEMBL5754	Homo sapiens	Inhibition	%	1.03
	8205911	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	1.0	CHEMBL5754	Homo sapiens	Inhibition	%	1.0
	8206043	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.24	CHEMBL5754	Homo sapiens	Inhibition	%	-0.24
	8206267	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.08	CHEMBL5754	Homo sapiens	Inhibition	%	0.08
	8206319	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	-0.39	CHEMBL5754	Homo sapiens	Inhibition	%	-0.39
	8206543	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.02	CHEMBL5754	Homo sapiens	Inhibition	%	2.02
	8206686	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	1.73	CHEMBL5754	Homo sapiens	Inhibition	%	1.73
	8206866	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	2.41	CHEMBL5754	Homo sapiens	Inhibition	%	2.41
	8207090	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	3.46	CHEMBL5754	Homo sapiens	Inhibition	%	3.46
	8207216	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	1.87	CHEMBL5754	Homo sapiens	Inhibition	%	1.87
	8207570	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.64	CHEMBL5754	Homo sapiens	Inhibition	%	3.64
	8207702	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	5.35	CHEMBL5754	Homo sapiens	Inhibition	%	5.35
	8207926	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	2.91	CHEMBL5754	Homo sapiens	Inhibition	%	2.91
	8208071	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	2.05	CHEMBL5754	Homo sapiens	Inhibition	%	2.05
	8208427	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	2.28	CHEMBL5754	Homo sapiens	Inhibition	%	2.28
	8208593	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	0.19	CHEMBL5754	Homo sapiens	Inhibition	%	0.19
	8208950	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.74	CHEMBL5754	Homo sapiens	Inhibition	%	3.74
	8209055	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.24	CHEMBL5754	Homo sapiens	Inhibition	%	1.24
	8209279	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.22	CHEMBL5754	Homo sapiens	Inhibition	%	1.22
	8209395	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	0.3	CHEMBL5754	Homo sapiens	Inhibition	%	0.3
	8209769	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	0.63	CHEMBL5754	Homo sapiens	Inhibition	%	0.63
	8209905	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.45	CHEMBL5754	Homo sapiens	Inhibition	%	5.45
	8210129	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	4.58	CHEMBL5754	Homo sapiens	Inhibition	%	4.58
	8210270	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	-0.01	CHEMBL5754	Homo sapiens	Inhibition	%	-0.01
	8210630	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	0.81	CHEMBL5754	Homo sapiens	Inhibition	%	0.81
	8210889	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	1.96	CHEMBL5754	Homo sapiens	Inhibition	%	1.96
	8211033	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	2.41	CHEMBL5754	Homo sapiens	Inhibition	%	2.41
	8211427	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	2.82	CHEMBL5754	Homo sapiens	Inhibition	%	2.82
	8211550	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	-0.31	CHEMBL5754	Homo sapiens	Inhibition	%	-0.31
	8211903	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	4.75	CHEMBL5754	Homo sapiens	Inhibition	%	4.75
	8212259	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	6.29	CHEMBL5754	Homo sapiens	Inhibition	%	6.29
	8212400	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.0	CHEMBL5754	Homo sapiens	Inhibition	%	2.0
	8212757	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.79	CHEMBL5754	Homo sapiens	Inhibition	%	1.79
	8212927	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	1.73	CHEMBL5754	Homo sapiens	Inhibition	%	1.73
	8213280	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	11.04	CHEMBL5754	Homo sapiens	Inhibition	%	11.04
	8213608	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.05	CHEMBL5754	Homo sapiens	Inhibition	%	-0.05
	8213721	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.26	CHEMBL5754	Homo sapiens	Inhibition	%	2.26
	8213945	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	0.44	CHEMBL5754	Homo sapiens	Inhibition	%	0.44
	8214092	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	2.61	CHEMBL5754	Homo sapiens	Inhibition	%	2.61
	8214453	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	32.03	CHEMBL5754	Homo sapiens	Inhibition	%	32.03
	8214587	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	1.68	CHEMBL5754	Homo sapiens	Inhibition	%	1.68
	8214963	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	4.57	CHEMBL5754	Homo sapiens	Inhibition	%	4.57
	8215214	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.4	CHEMBL5754	Homo sapiens	Inhibition	%	1.4
	8215367	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	4.85	CHEMBL5754	Homo sapiens	Inhibition	%	4.85
	8215591	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	3.62	CHEMBL5754	Homo sapiens	Inhibition	%	3.62
	8215755	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.75	CHEMBL5754	Homo sapiens	Inhibition	%	0.75
	8215874	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	1.95	CHEMBL5754	Homo sapiens	Inhibition	%	1.95
	8216098	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	2.9	CHEMBL5754	Homo sapiens	Inhibition	%	2.9
	8216217	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	1.2	CHEMBL5754	Homo sapiens	Inhibition	%	1.2
	8216577	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	7.29	CHEMBL5754	Homo sapiens	Inhibition	%	7.29
	8216715	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	3.26	CHEMBL5754	Homo sapiens	Inhibition	%	3.26
	8216939	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	2.4	CHEMBL5754	Homo sapiens	Inhibition	%	2.4
	8217073	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.85	CHEMBL5754	Homo sapiens	Inhibition	%	2.85
	8217247	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	-0.01	CHEMBL5754	Homo sapiens	Inhibition	%	-0.01
	8217471	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.55	CHEMBL5754	Homo sapiens	Inhibition	%	0.55
	8217602	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	34.85	CHEMBL5754	Homo sapiens	Inhibition	%	34.85
	8217927	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	1.71	CHEMBL5754	Homo sapiens	Inhibition	%	1.71
	8218266	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	2.12	CHEMBL5754	Homo sapiens	Inhibition	%	2.12
	8218393	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.02	CHEMBL5754	Homo sapiens	Inhibition	%	2.02
	8218760	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	1.52	CHEMBL5754	Homo sapiens	Inhibition	%	1.52
	8218891	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	6.22	CHEMBL5754	Homo sapiens	Inhibition	%	6.22
	8219115	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.56	CHEMBL5754	Homo sapiens	Inhibition	%	0.56
	8219275	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	5.04	CHEMBL5754	Homo sapiens	Inhibition	%	5.04
	8219525	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.82	CHEMBL5754	Homo sapiens	Inhibition	%	1.82
	8219910	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	2.28	CHEMBL5754	Homo sapiens	Inhibition	%	2.28
	8220079	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.71	CHEMBL5754	Homo sapiens	Inhibition	%	2.71
	8220432	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	1.16	CHEMBL5754	Homo sapiens	Inhibition	%	1.16
	8220546	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	2.56	CHEMBL5754	Homo sapiens	Inhibition	%	2.56
	8220770	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.64	CHEMBL5754	Homo sapiens	Inhibition	%	1.64
	8220908	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	33.09	CHEMBL5754	Homo sapiens	Inhibition	%	33.09
	8221268	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	8.22	CHEMBL5754	Homo sapiens	Inhibition	%	8.22
	8221401	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.88	CHEMBL5754	Homo sapiens	Inhibition	%	1.88
	8221790	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.87	CHEMBL5754	Homo sapiens	Inhibition	%	0.87
	8221921	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	76.59	CHEMBL5754	Homo sapiens	Inhibition	%	76.59
	8222145	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	3.04	CHEMBL5754	Homo sapiens	Inhibition	%	3.04
	8222243	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	0.67	CHEMBL5754	Homo sapiens	Inhibition	%	0.67
	8222601	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	2.7	CHEMBL5754	Homo sapiens	Inhibition	%	2.7
	8222719	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	16.76	CHEMBL5754	Homo sapiens	Inhibition	%	16.76
	8222943	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	-0.05	CHEMBL5754	Homo sapiens	Inhibition	%	-0.05
	8223087	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	5.32	CHEMBL5754	Homo sapiens	Inhibition	%	5.32
	8223440	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	3.1	CHEMBL5754	Homo sapiens	Inhibition	%	3.1
	8223601	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.83	CHEMBL5754	Homo sapiens	Inhibition	%	2.83
	8223851	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	2.52	CHEMBL5754	Homo sapiens	Inhibition	%	2.52
	8224237	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	4.16	CHEMBL5754	Homo sapiens	Inhibition	%	4.16
	8224407	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.23	CHEMBL5754	Homo sapiens	Inhibition	%	2.23
	8224766	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.14	CHEMBL5754	Homo sapiens	Inhibition	%	2.14
	8225104	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	3.1	CHEMBL5754	Homo sapiens	Inhibition	%	3.1
	8225238	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.4	CHEMBL5754	Homo sapiens	Inhibition	%	3.4
	8225600	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.03	CHEMBL5754	Homo sapiens	Inhibition	%	1.03
	8225735	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.09	CHEMBL5754	Homo sapiens	Inhibition	%	5.09
	8225959	CHEMBL1961976	GSK_PKIS: MARK4 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.24	CHEMBL5754	Homo sapiens	Inhibition	%	1.24
	8226117	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.98	CHEMBL5754	Homo sapiens	Inhibition	%	0.98
	8226466	CHEMBL1961977	GSK_PKIS: MARK4 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	7.4	CHEMBL5754	Homo sapiens	Inhibition	%	7.4
active	9516691	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	=	Ki	nM	1584.89	CHEMBL5754	Homo sapiens	pKi		5.8
inactive	9516692	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516693	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	50.12	CHEMBL5754	Homo sapiens	pKi		7.3
inactive	9516694	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516695	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516696	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	398.11	CHEMBL5754	Homo sapiens	pKi		6.4
inactive	9516697	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516698	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	50.12	CHEMBL5754	Homo sapiens	pKi		7.3
active	9516699	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	251.19	CHEMBL5754	Homo sapiens	pKi		6.6
inactive	9516700	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516701	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516702	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	7.943	CHEMBL5754	Homo sapiens	pKi		8.1
inactive	9516703	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516704	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516705	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516706	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516707	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Ki	nM	100.0	CHEMBL5754	Homo sapiens	pKi		7.0
inactive	9516708	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516709	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516710	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516711	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516712	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Ki	nM	1000.0	CHEMBL5754	Homo sapiens	pKi		6.0
active	9516713	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	=	Ki	nM	3981.07	CHEMBL5754	Homo sapiens	pKi		5.4
active	9516714	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	=	Ki	nM	630.96	CHEMBL5754	Homo sapiens	pKi		6.2
inactive	9516715	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516716	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516717	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516718	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	100.0	CHEMBL5754	Homo sapiens	pKi		7.0
active	9516719	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	398.11	CHEMBL5754	Homo sapiens	pKi		6.4
inactive	9516720	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516721	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Ki	nM	100.0	CHEMBL5754	Homo sapiens	pKi		7.0
inactive	9516722	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
inactive	9516723	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516724	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	0.7943	CHEMBL5754	Homo sapiens	pKi		9.1
inactive	9516725	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9516726	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	0.5012	CHEMBL5754	Homo sapiens	pKi		9.3
inactive	9516727	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	5011.87	CHEMBL5754	Homo sapiens	pKi		5.3
active	9520642	CHEMBL1963713	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: MARK4	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	=	Ki	nM	79.43	CHEMBL5754	Homo sapiens	pKi		7.1
	10839399	CHEMBL2014965	Inhibition of MARK4 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	10839607	CHEMBL2015154	Inhibition of MARK4 assessed as residual activity at 10 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	19.0	CHEMBL5754	Homo sapiens	Activity	%	19.0
	10839634	CHEMBL2016286	Inhibition of MARK4 assessed as residual activity at 1 uM relative to control	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Activity	%	37.0	CHEMBL5754	Homo sapiens	Activity	%	37.0
	12046357	CHEMBL2157284	Inhibition of MARK4 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	0.3	CHEMBL5754	Homo sapiens	INH	%	0.3
	12170784	CHEMBL2209911	Inhibition of MARK4 assessed as residual activity at 1 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	12170915	CHEMBL2213911	Inhibition of MARK4 assessed as residual activity at 10 uM	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	92.0	CHEMBL5754	Homo sapiens	Activity	%	92.0
	12172357	CHEMBL2210622	Inhibition of MARK4 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	78.0	CHEMBL5754	Homo sapiens	Activity	%	78.0
	12183847	CHEMBL2211541	Inhibition of MARK4	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	pIC50		5.0
	12672989	CHEMBL2339721	Inhibition of recombinant MARK4 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336379	=	Activity	%	29.0	CHEMBL5754	Homo sapiens	Activity	%	29.0
	12672990	CHEMBL2339721	Inhibition of recombinant MARK4 (unknown origin) assessed as residual activity using [gamma-33P]ATP as substrate at 1 uM	B	CC[C@H](CO)Nc1nc(NC(=N)N)c2ncn(C(C)C)c2n1		CHEMBL2336377	=	Activity	%	38.0	CHEMBL5754	Homo sapiens	Activity	%	38.0
	12727735	CHEMBL2351169	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1		CHEMBL2348865	=	Activity	%	90.0	CHEMBL5754	Homo sapiens	Activity	%	90.0
	12729023	CHEMBL2351929	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 1 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	12730166	CHEMBL2351169	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 10 uM relative to control	B	CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1		CHEMBL2348862	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	13375782	CHEMBL2404176	Inhibition of MARK4 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	INH	%	0.0
	13436266	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436267	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436268	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436269	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436270	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436271	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436272	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436273	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436274	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436275	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436276	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13436277	CHEMBL2422247	Inhibition of MARK4 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	<	Inhibition	%	35.0	CHEMBL5754	Homo sapiens	INH	%	35.0
	13439818	CHEMBL2426963	Competitive binding affinity to MARK4 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	13442628	CHEMBL2426963	Competitive binding affinity to MARK4 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	67.0	CHEMBL5754	Homo sapiens	INH	%	67.0
	13445651	CHEMBL2426963	Competitive binding affinity to MARK4 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	13451638	CHEMBL2426963	Competitive binding affinity to MARK4 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	15072443	CHEMBL3380780	Inhibition of MARK4 (unknown origin) assessed as remaining enzyme activity at 10 uM by radioactive [33P]-ATP filter binding assay	B	Cc1ccc(-c2cc(C(=O)Nc3ccnc(Cl)c3)nn2-c2ccc3ccccc3n2)cc1		CHEMBL3338802	=	Activity	%	76.0	CHEMBL5754	Homo sapiens	Activity	%	76.0
	15251840	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL443738	=	Activity	%	57.0	CHEMBL5754	Homo sapiens	Activity	%	57.0
	15251957	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427170	=	Activity	%	88.0	CHEMBL5754	Homo sapiens	Activity	%	88.0
	15252059	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427171	=	Activity	%	97.0	CHEMBL5754	Homo sapiens	Activity	%	97.0
	15252704	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(O)cc3s2)=N1		CHEMBL3427172	=	Activity	%	88.0	CHEMBL5754	Homo sapiens	Activity	%	88.0
	15252806	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)CS3)sc2c1		CHEMBL3427173	=	Activity	%	81.0	CHEMBL5754	Homo sapiens	Activity	%	81.0
	15252908	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)CS3)sc2c1		CHEMBL3427174	=	Activity	%	79.0	CHEMBL5754	Homo sapiens	Activity	%	79.0
	15253582	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427175	=	Activity	%	83.0	CHEMBL5754	Homo sapiens	Activity	%	83.0
	15253684	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COC(=O)[C@@H]1CSC(c2nc3ccc(OC)cc3s2)=N1		CHEMBL3427176	=	Activity	%	84.0	CHEMBL5754	Homo sapiens	Activity	%	84.0
	15253786	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427177	=	Activity	%	81.0	CHEMBL5754	Homo sapiens	Activity	%	81.0
	15254452	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	COc1ccc2nc(C3=N[C@H](C(=O)O)C(C)(C)S3)sc2c1		CHEMBL3427178	=	Activity	%	47.0	CHEMBL5754	Homo sapiens	Activity	%	47.0
	15254554	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@H]1C(=O)O		CHEMBL3427179	=	Activity	%	85.0	CHEMBL5754	Homo sapiens	Activity	%	85.0
	15254656	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	CC1(C)SC(c2nc3ccc(O)cc3s2)=N[C@@H]1C(=O)O		CHEMBL3427180	=	Activity	%	73.0	CHEMBL5754	Homo sapiens	Activity	%	73.0
	15255347	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427181	=	Activity	%	77.0	CHEMBL5754	Homo sapiens	Activity	%	77.0
	15255449	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cc(O)ccc3n2)=N1		CHEMBL3427182	=	Activity	%	80.0	CHEMBL5754	Homo sapiens	Activity	%	80.0
	15256181	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427183	=	Activity	%	81.0	CHEMBL5754	Homo sapiens	Activity	%	81.0
	15256283	CHEMBL3428241	Inhibition of MARK4 (unknown origin) assessed as remaining activity at 100 uM by radioactive filter binding assay in presence of [33P]-ATP relative to control	B	O=C(O)[C@@H]1CSC(c2ccc3cccc(O)c3n2)=N1		CHEMBL3427184	=	Activity	%	76.0	CHEMBL5754	Homo sapiens	Activity	%	76.0
	15756923	CHEMBL3631287	Inhibition of MARK4 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	13.79	CHEMBL5754	Homo sapiens	INH	%	13.79
	15757800	CHEMBL3631287	Inhibition of MARK4 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	39.1	CHEMBL5754	Homo sapiens	INH	%	39.1
	15758779	CHEMBL3631287	Inhibition of MARK4 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	12.52	CHEMBL5754	Homo sapiens	INH	%	12.52
	16431895	CHEMBL3747988	Inhibition of human MARK4 using [KKKVSRSGLYRSPSMPENLNRPR] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	uM	10.0
	16451506	CHEMBL3760629	Inhibition of MARK4 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	2.5	CHEMBL5754	Homo sapiens	INH	%	2.5
	16611981	CHEMBL3815475	Inhibition of human MARK4 (2 to 752 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	35.0	CHEMBL5754	Homo sapiens	Activity	%	35.0
	16614532	CHEMBL3816730	Inhibition of human MARK4 at 1 uM using [KKKVSRSGLYRSPSMPENLNRPR] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	1.0	CHEMBL5754	Homo sapiens	INH	%	1.0
	16618166	CHEMBL3817265	Inhibition of full length recombinant human GST-tagged MARK4 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	16654137	CHEMBL3829185	Inhibition of human MARK4 (2 to 752 residues) assessed as remaining enzyme activity at 50 uM after 30 mins by 33P-ATP filter-binding assay	B	Cc1cc(=O)c2c(O)cc(O)c([C@H]3CCN(C)C[C@H]3O)c2o1		CHEMBL1077604	=	Activity	%	92.0	CHEMBL5754	Homo sapiens	Activity	%	92.0
	16804179	CHEMBL3869770	Inhibition of human recombinant full length GST-tagged MARK4 expressed in baculovirus expression system at 200 nM by Z'-LYTE assay	B	Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1		CHEMBL3979920	=	Inhibition	%	52.0	CHEMBL5754	Homo sapiens	INH	%	52.0
	16837349	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N(C2CCCCC2)c2nc(Nc3ccccc3)ncc21		CHEMBL3883802	=	IC50	nM	8600.0	CHEMBL5754	Homo sapiens	IC50	nM	8600.0
	16837350	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	Cn1cc(N2C(=O)c3nc(Nc4ccccc4)ncc3C2(C)C)cn1		CHEMBL3883776	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837351	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)CN(C2CCCCC2)c2nc(Nc3ccccc3)ncc21		CHEMBL3884098	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837352	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N(C2CCCCC2)c2nc(Nc3cccc(N4CCNCC4)c3)ncc21		CHEMBL3884535	=	IC50	nM	920.0	CHEMBL5754	Homo sapiens	IC50	nM	920.0
	16837353	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N(C2CCCCC2)c2nc(Nc3cccnc3)ncc21		CHEMBL3883548	=	IC50	nM	5990.0	CHEMBL5754	Homo sapiens	IC50	nM	5990.0
	16837354	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N(c2ccccc2)c2nc(Nc3ccccc3)ncc21		CHEMBL3883398	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837355	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)Nc2nc(Nc3ccccc3)ncc21		CHEMBL3885486	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837356	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC[C@@H](C)N1C(=O)C(C)(C)c2cnc(Nc3cccnc3)nc21		CHEMBL3883766	=	IC50	nM	5910.0	CHEMBL5754	Homo sapiens	IC50	nM	5910.0
	16837357	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC(C)[C@H](C)N1C(=O)C(C)(C)c2cnc(Nc3ccccc3)nc21		CHEMBL3883412	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837358	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	C[C@@H](c1ccccc1)N1C(=O)C(C)(C)c2cnc(Nc3cccnc3)nc21		CHEMBL3884884	=	IC50	nM	2750.0	CHEMBL5754	Homo sapiens	IC50	nM	2750.0
	16837359	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N(C(C)(C)c2ccccc2)c2nc(Nc3cccnc3)ncc21		CHEMBL3884929	=	IC50	nM	3760.0	CHEMBL5754	Homo sapiens	IC50	nM	3760.0
	16837360	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N([C@H](c2ccccc2)C(F)F)c2nc(Nc3ccccc3)ncc21		CHEMBL3885257	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837361	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	C[C@@H](c1ccc(F)cc1)N1C(=O)C(C)(C)c2cnc(Nc3cccnc3)nc21		CHEMBL3884179	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	nM	10000.0
	16837362	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N([C@H]2CCc3ccccc32)c2nc(Nc3cccnc3)ncc21		CHEMBL3883433	=	IC50	nM	520.0	CHEMBL5754	Homo sapiens	IC50	nM	520.0
	16837363	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	C[C@@H](c1cccc(O)c1)N1C(=O)C(C)(C)c2cnc(Nc3cccnc3)nc21		CHEMBL3884318	=	IC50	nM	270.0	CHEMBL5754	Homo sapiens	IC50	nM	270.0
	16837364	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	21.0	CHEMBL5754	Homo sapiens	IC50	nM	21.0
	16837365	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N([C@H]2CCc3c(N)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3883979	=	IC50	nM	450.0	CHEMBL5754	Homo sapiens	IC50	nM	450.0
	16837366	CHEMBL3876024	Inhibition of human MARK4 expressed in HEK293T cells coexpressing tau protein assessed as reduction in tau phosphorylation at Ser262 residues by AlphaLisa assay	B	CC1(C)C(=O)N([C@H]2CCc3c(NS(C)(=O)=O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884344	=	IC50	nM	180.0	CHEMBL5754	Homo sapiens	IC50	nM	180.0
Inactive	17917693	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917694	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917695	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917696	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917697	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917698	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917699	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917700	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917701	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917702	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917703	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	976.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	976.0
Inactive	17917704	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917705	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917706	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917707	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917708	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917709	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917710	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917711	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917712	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917713	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917714	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917715	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917716	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917717	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	475.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	475.0
Inactive	17917718	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917719	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917720	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917721	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917722	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917723	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917724	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917725	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917726	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917727	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917728	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917729	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	=	Kd	nM	25.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	25.0
Inactive	17917730	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917731	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917732	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917733	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917734	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917735	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917736	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917737	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917738	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917739	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917740	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	232.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	232.0
Inactive	17917741	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917742	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917743	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917744	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917745	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917746	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Kd	nM	140.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	140.0
Inactive	17917747	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917748	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	=	Kd	nM	29.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	29.0
Inactive	17917749	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917750	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917751	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917752	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	28.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	28.0
Inactive	17917753	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917754	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917755	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917756	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	72.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	72.0
Inactive	17917757	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917758	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917759	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917760	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917761	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917762	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917763	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917764	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917765	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917766	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917767	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917768	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917769	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917770	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917771	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917772	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917773	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917774	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917775	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917776	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917777	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917778	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917779	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917780	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917781	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917782	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917783	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917784	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917785	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917786	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917787	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917788	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917789	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917790	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917791	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917792	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917793	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917794	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917795	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917796	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917797	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917798	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917799	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917800	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917801	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917802	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917803	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917804	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917805	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917806	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917807	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917808	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917809	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917810	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917811	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917812	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917813	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917814	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917815	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917816	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917817	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917818	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917819	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917820	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	1035.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	1035.0
Inactive	17917821	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917822	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917823	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917824	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917825	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917826	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917827	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917828	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917829	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917830	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917831	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917832	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917833	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917834	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917835	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917836	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917837	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917838	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917839	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917840	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917841	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917842	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917843	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917844	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917845	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917846	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917847	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917848	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917849	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917850	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917851	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917852	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917853	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917854	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917855	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917856	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917857	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917858	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917859	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917860	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917861	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917862	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917863	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917864	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917865	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917866	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917867	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917868	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917869	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917870	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917871	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917872	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917873	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917874	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917875	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917876	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917877	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917878	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917879	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917880	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917881	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917882	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917883	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917884	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	8.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	8.0
Inactive	17917885	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917886	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	9.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	9.0
Uncertain	17917887	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	=	Kd	nM	36.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	36.0
Inactive	17917888	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917889	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917890	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917891	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917892	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917893	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917894	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917895	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917896	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917897	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917898	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917899	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917900	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917901	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917902	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917903	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917904	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917905	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17917906	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	30000.0
Active	17917907	CHEMBL3991783	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	73.0	CHEMBL5754	Homo sapiens	Kd apparent	nM	73.0
	18069851	CHEMBL4015078	Inhibition of human MARK4 (2 to 752 residues) at 1 uM after 5 mins in presence of [33P]ATP by filter binding assay relative to control	B	O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1		CHEMBL4060768	=	Inhibition	%	32.0	CHEMBL5754	Homo sapiens	INH	%	32.0
	18114263	CHEMBL4025231	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	91.0	CHEMBL5754	Homo sapiens	Activity	%	91.0
	18153071	CHEMBL4034395	Inhibition of MARK4 Lysine 2 labelling site (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	2.1	CHEMBL5754	Homo sapiens	INH	%	2.1
	18153196	CHEMBL4034536	Inhibition of MARK4 (unknown origin) labeling at conserved Lysine1 at 10 uM relative to control	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	0.8	CHEMBL5754	Homo sapiens	INH	%	0.8
	18153278	CHEMBL4034394	Inhibition of MARK4 (unknown origin) labeling at conserved Lysine1 (EVAIKIIDK) at 10 uM relative to control	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-8.5	CHEMBL5754	Homo sapiens	INH	%	-8.5
	18203755	CHEMBL4044042	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	87.0	CHEMBL5754	Homo sapiens	Activity	%	87.0
	18211556	CHEMBL4045757	Inhibition of MARK4 conserved Lys1 (EVAIKIIDK) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-23.4	CHEMBL5754	Homo sapiens	INH	%	-23.4
	18211902	CHEMBL4045998	Inhibition of MARK4 conserved Lys1 (EVAIKIIDK) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	-6.7	CHEMBL5754	Homo sapiens	INH	%	-6.7
	18218987	CHEMBL4047242	Inhibition of MARK4 (unknown origin) assessed as residual activity relative to control	B	C=CC(=O)Nc1cccc(CNc2cc(Nc3ccccc3)ncc2C(N)=O)c1		CHEMBL4065693	<=	Activity	%	10.0	CHEMBL5754	Homo sapiens	Activity	%	10.0
	18232129	CHEMBL4050373	Inhibition of human MARK4 assessed as residual activity at 1 uM in presence of [33P]ATP by filter binding assay relative to control	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Activity	%	91.0	CHEMBL5754	Homo sapiens	Activity	%	91.0
	18253451	CHEMBL4055009	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	79.0	CHEMBL5754	Homo sapiens	Activity	%	79.0
	18253452	CHEMBL4055009	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	93.0	CHEMBL5754	Homo sapiens	Activity	%	93.0
	18265899	CHEMBL4057349	Inhibition of MARK4 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	37.0	CHEMBL5754	Homo sapiens	INH	%	37.0
	18266093	CHEMBL4057543	Inhibition of MARK4 (unknown origin) at 0.49 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(NC(=O)C3CC3)noc2c1		CHEMBL4088455	=	Inhibition	%	8.7	CHEMBL5754	Homo sapiens	INH	%	8.7
	18282768	CHEMBL4120353	Inhibition of MARK4 (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	37.0	CHEMBL5754	Homo sapiens	INH	%	37.0
	18282937	CHEMBL4120522	Inhibition of MARK4 (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	0.7	CHEMBL5754	Homo sapiens	INH	%	0.7
	18283161	CHEMBL4120746	Inhibition of MARK4 (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	7.3	CHEMBL5754	Homo sapiens	INH	%	7.3
	18440297	CHEMBL4157121	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	87.0	CHEMBL5754	Homo sapiens	Activity	%	87.0
	18449832	CHEMBL4178069	Inhibition of human MARK4 (2 to 752 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	116.0	CHEMBL5754	Homo sapiens	Activity	%	116.0
	18449833	CHEMBL4178070	Inhibition of human MARK4 (1 to 367 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	116.0	CHEMBL5754	Homo sapiens	Activity	%	116.0
	18484253	CHEMBL4185900	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	52.0	CHEMBL5754	Homo sapiens	Activity	%	52.0
	18484737	CHEMBL4185900	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	85.0	CHEMBL5754	Homo sapiens	Activity	%	85.0
	18507719	CHEMBL4191043	Inhibition of recombinant full-length human MARK4 at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	-3.0	CHEMBL5754	Homo sapiens	INH	%	-3.0
	18653529	CHEMBL4230139	Inhibition of MARK4 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	-4.0	CHEMBL5754	Homo sapiens	INH	%	-4.0
	18653530	CHEMBL4230139	Inhibition of MARK4 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	-1.0	CHEMBL5754	Homo sapiens	INH	%	-1.0
	18655435	CHEMBL4230800	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	90.0	CHEMBL5754	Homo sapiens	Activity	%	90.0
	18751039	CHEMBL4263857	Inhibition of MARK4 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	14.0	CHEMBL5754	Homo sapiens	INH	%	14.0
	18752008	CHEMBL4264389	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	87.0	CHEMBL5754	Homo sapiens	Activity	%	87.0
Active	18776228	CHEMBL4269085	Inhibition of MARK4-mediated tau phosphorylation in human MCF7 cells at IC50 after 24 hrs by flow cytometric analysis	B	COc1ccc(Nc2c(-c3ccco3)oc3ccccc3c2=O)cc1		CHEMBL4279484		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18776232	CHEMBL4269085	Inhibition of MARK4-mediated tau phosphorylation in human MCF7 cells at IC50 after 24 hrs by flow cytometric analysis	B	O=c1c(Nc2ccc(I)cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4293547		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18776233	CHEMBL4269085	Inhibition of MARK4-mediated tau phosphorylation in human MCF7 cells at IC50 after 24 hrs by flow cytometric analysis	B	O=c1c(Nc2ccc([N+](=O)[O-])cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4282948		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18776264	CHEMBL4269073	Binding affinity to MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 up to 10 uM by fluorescence based Stern-Volmer plot analysis	B	COc1ccc(Nc2c(-c3ccco3)oc3ccccc3c2=O)cc1		CHEMBL4279484		Activity			CHEMBL5754	Homo sapiens	Activity		
Active	18776265	CHEMBL4269073	Binding affinity to MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 up to 10 uM by fluorescence based Stern-Volmer plot analysis	B	O=c1c(Nc2ccc(I)cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4293547		Activity			CHEMBL5754	Homo sapiens	Activity		
Active	18776266	CHEMBL4269073	Binding affinity to MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 up to 10 uM by fluorescence based Stern-Volmer plot analysis	B	O=c1c(Nc2ccc([N+](=O)[O-])cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4282948		Activity			CHEMBL5754	Homo sapiens	Activity		
Active	18776267	CHEMBL4269072	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 3 to 10 uM by dot blot assay	B	COc1ccc(Nc2c(-c3ccco3)oc3ccccc3c2=O)cc1		CHEMBL4279484		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18776268	CHEMBL4269072	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 3 to 10 uM by dot blot assay	B	O=c1c(Nc2ccc(I)cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4293547		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18776269	CHEMBL4269072	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 3 to 10 uM by dot blot assay	B	O=c1c(Nc2ccc([N+](=O)[O-])cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4282948		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	18776270	CHEMBL4269071	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 in presence of [gamma-32P]ATP by ATPase assay	B	COc1ccc(Nc2c(-c3ccco3)oc3ccccc3c2=O)cc1		CHEMBL4279484	=	IC50	nM	5560.0	CHEMBL5754	Homo sapiens	IC50	uM	5.56
	18776271	CHEMBL4269071	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 in presence of [gamma-32P]ATP by ATPase assay	B	O=c1c(Nc2ccc(I)cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4293547	=	IC50	nM	1980.0	CHEMBL5754	Homo sapiens	IC50	uM	1.98
	18776272	CHEMBL4269071	Inhibition of MARK4 (unknown origin) (59 to 368 residues) expressed in Escherichia coli M15 in presence of [gamma-32P]ATP by ATPase assay	B	O=c1c(Nc2ccc([N+](=O)[O-])cc2)c(-c2ccco2)oc2c(Cl)cc(Cl)cc12		CHEMBL4282948	=	IC50	nM	2120.0	CHEMBL5754	Homo sapiens	IC50	uM	2.12
	18858053	CHEMBL4307899	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	64.0	CHEMBL5754	Homo sapiens	Activity	%	64.0
	18892650	CHEMBL4314599	Inhibition of recombinant full-length human MARK4 assessed as residual activity at 10 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	123.0	CHEMBL5754	Homo sapiens	Activity	%	123.0
	18919360	CHEMBL4322734	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged MARK4 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	6.0	CHEMBL5754	Homo sapiens	Kd	nM	6.0
Not Determined	18919374	CHEMBL4322734	Binding affinity to recombinant full-length N-terminal His-FLAG-tagged MARK4 (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489		Kd			CHEMBL5754	Homo sapiens	Kd		
	18938063	CHEMBL4327758	Inhibition of human MARK4 assessed as residual activity at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	90.19	CHEMBL5754	Homo sapiens	Activity	%	90.19
	18938064	CHEMBL4327758	Inhibition of human MARK4 assessed as residual activity at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	93.81	CHEMBL5754	Homo sapiens	Activity	%	93.81
	18938603	CHEMBL4328122	Inhibition of human MARK4 assessed as residual activity at 100 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL5754	Homo sapiens	Activity	%	65.0
	18938983	CHEMBL4328486	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.114	CHEMBL5754	Homo sapiens	IC50	10'-10M	1.14
	18958964	CHEMBL4333486	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	65.0	CHEMBL5754	Homo sapiens	Activity	%	65.0
	18964439	CHEMBL4335158	Inhibition of recombinant full length human MARK4 assessed as residual activity at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	92.0	CHEMBL5754	Homo sapiens	Activity	%	92.0
	18964440	CHEMBL4335158	Inhibition of recombinant full length human MARK4 assessed as residual activity at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	113.0	CHEMBL5754	Homo sapiens	Activity	%	113.0
Active	18967171	CHEMBL4336198	Inhibition of recombinant human MARK4 at 10 uM incubated for 2 hrs by [gamma32P]ATP assay	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18967172	CHEMBL4336198	Inhibition of recombinant human MARK4 at 10 uM incubated for 2 hrs by [gamma32P]ATP assay	B	O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23		CHEMBL6246		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	18967173	CHEMBL4336199	Inhibition of recombinant human MARK4 incubated for 2 hrs by [gamma32P]ATP assay	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197	=	IC50	nM	1770.0	CHEMBL5754	Homo sapiens	IC50	uM	1.77
Dose-dependent effect	18967174	CHEMBL4336199	Inhibition of recombinant human MARK4 incubated for 2 hrs by [gamma32P]ATP assay	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18967175	CHEMBL4336200	Inhibition of MARK4 in human SH-SY5Y cells assessed as reduction in tau phosphorylation at IC50 after 24 hrs by flow cytometric analysis	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	18967176	CHEMBL4336201	Binding affinity to recombinant human MARK 4 by fluorescence based Stem-Volme plot analysis	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197	=	Ka	10'7/M	5.2	CHEMBL5754	Homo sapiens	Ka	10'7/M	5.2
Active	18967190	CHEMBL4336215	Inhibition of MARK4 in human MCF7 cells assessed as reduction in ROS level at IC50 after 5 to 6 hrs by DCFDA staining using spectroflourimetric analysis	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	18967191	CHEMBL4336216	Inhibition of MARK4 in human HepG2 cells assessed as reduction in ROS level at IC50 after 5 to 6 hrs by DCFDA staining using spectroflourimetric analysis	B	COc1c(O)cc2oc3cc(O)c(CC=C(C)C)c(O)c3c(=O)c2c1CC=C(C)C		CHEMBL323197		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	18971975	CHEMBL4336985	Inhibition of recombinant full length human MARK4 assessed as residual activity at 10 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	89.0	CHEMBL5754	Homo sapiens	Activity	%	89.0
Not Active	19039706	CHEMBL4351936	Inhibition of recombinant full-length human MARK4 at 10 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	19041173	CHEMBL4352434	Inhibition of human MARK4 at 10 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	19059677	CHEMBL4357978	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	95.0	CHEMBL5754	Homo sapiens	Activity	%	95.0
	19090242	CHEMBL4365816	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	95.0	CHEMBL5754	Homo sapiens	Activity	%	95.0
	19091995	CHEMBL4366469	Inhibition of human MARK4 at 100 nM using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	1.56	CHEMBL5754	Homo sapiens	INH	%	1.56
	19114473	CHEMBL4371446	Binding affinity to MARK4 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	B	COc1cc2c(Oc3ccc(NS(=O)(=O)c4cc(F)ccc4F)cc3F)ccnc2cc1OCCCN1CCN(C)CC1		CHEMBL4443828	=	Kd	nM	5975.0	CHEMBL5754	Homo sapiens	Kd(free)	uM	5.975
	19144637	CHEMBL4377653	Inhibition of full-length recombinant human MARK4 at 1 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	77.0	CHEMBL5754	Homo sapiens	INH	%	77.0
	19147923	CHEMBL4379397	Inhibition of recombinant full length human MARK4 using KKKVSRSGLYRSP as substrate incubated for 40 mins in presence of [gamma-33ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL5754	Homo sapiens	IC50	uM	10.0
	19159505	CHEMBL4382609	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	6.0	CHEMBL5754	Homo sapiens	Activity	%	6.0
	19191502	CHEMBL4389328	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	87.0	CHEMBL5754	Homo sapiens	INH	%	87.0
	19191991	CHEMBL4389805	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	77.0	CHEMBL5754	Homo sapiens	INH	%	77.0
	19200247	CHEMBL4391431	Binding affinity to wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	35.0	CHEMBL5754	Homo sapiens	Activity	%	35.0
	19266492	CHEMBL4405442	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL5754	Homo sapiens	INH	%	50.0
	19292317	CHEMBL4411568	Inhibition of N-terminal GST tagged full length human MARK4 (1 to 688 end residues) expressed in baculovirus expression system at 1 uM in presence of ATP at its Km level relative to control	B	Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1		CHEMBL4458435	=	Inhibition	%	59.0	CHEMBL5754	Homo sapiens	INH	%	59.0
	19296668	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccccc43)nn2)cc1		CHEMBL4534332	>	IC50	nM	20000.0	CHEMBL5754	Homo sapiens	IC50	uM	20.0
	19296669	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4c(F)cccc43)nn2)cc1		CHEMBL4436753	=	IC50	nM	14100.0	CHEMBL5754	Homo sapiens	IC50	uM	14.1
	19296670	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(F)cc43)nn2)cc1		CHEMBL4466760	=	IC50	nM	18660.0	CHEMBL5754	Homo sapiens	IC50	uM	18.66
	19296671	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4c(Cl)cccc43)nn2)cc1		CHEMBL4447489	=	IC50	nM	12450.0	CHEMBL5754	Homo sapiens	IC50	uM	12.45
	19296672	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(Cl)cc43)nn2)cc1		CHEMBL4559911	=	IC50	nM	19240.0	CHEMBL5754	Homo sapiens	IC50	uM	19.24
	19296673	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(Br)cc43)nn2)cc1		CHEMBL4461598	>	IC50	nM	20000.0	CHEMBL5754	Homo sapiens	IC50	uM	20.0
	19296674	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4c(C)cccc43)nn2)cc1		CHEMBL4529234	=	IC50	nM	1540.0	CHEMBL5754	Homo sapiens	IC50	uM	1.54
	19296675	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(C)cc43)nn2)cc1		CHEMBL4563379	=	IC50	nM	8400.0	CHEMBL5754	Homo sapiens	IC50	uM	8.4
	19296676	CHEMBL4412615	Inhibition of human recombinant MARK4 expressed in Escherichia coli M15 cells after 2 hrs in presence of [gamma-32-P]ATP by TLC analysis based ATPase assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4ccc(F)c(Cl)c43)nn2)cc1		CHEMBL4543139	=	IC50	nM	10220.0	CHEMBL5754	Homo sapiens	IC50	uM	10.22
	19296677	CHEMBL4412616	Binding affinity to human recombinant MARK4 expressed in Escherichia coli M15 assessed as Stern-Volmer quenching constant by fluorescence emission spectral analysis	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4c(C)cccc43)nn2)cc1		CHEMBL4529234	=	Ka	10'7/M	6.0	CHEMBL5754	Homo sapiens	Ka	10'7/M	6.0
Active	19296703	CHEMBL4412639	Inhibition of MARK4 (unknown origin) at 10 uM after 60 mins by ADP-Glo luminescence assay	B	COc1ccc(Cn2cc(C(=O)N/N=C3/C(=O)Nc4c(C)cccc43)nn2)cc1		CHEMBL4529234		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
Active	19342253	CHEMBL4419777	Binding affinity to human MARK4	B	CN1CC(=O)N2[C@@H](Cc3cc4c(cc3[C@H]2c2c[nH]c3ccc(Cl)cc23)OCO4)C1=O		CHEMBL4461905		Activity			CHEMBL5754	Homo sapiens	Activity		
	20600590	CHEMBL4603542	Inhibition of recombinant full length human GST-tagged MARK4 expressed in baculovirus expression system using serine/threonine-25 peptide as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL5754	Homo sapiens	IC50	uM	100.0
	22423481	CHEMBL4674316	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	58.5	CHEMBL5754	Homo sapiens	Activity	%	58.5
	22423482	CHEMBL4674316	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	3.25	CHEMBL5754	Homo sapiens	Activity	%	3.25
	22843681	CHEMBL4720667	Inhibition of human MARK4 using KKKVSRSGLYRSPSMPENLNRPR as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	0.131	CHEMBL5754	Homo sapiens	IC50	10^-10M	1.31
	22844030	CHEMBL4721016	Inhibition of human MARK4 assessed as residual activity using KKKVSRSGLYRSPSMPENLNRPR as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	98.9	CHEMBL5754	Homo sapiens	Activity	%	98.9
	22844784	CHEMBL4721459	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	101.1	CHEMBL5754	Homo sapiens	Activity	%	101.1
	22952899	CHEMBL4766836	Inhibition of recombinant full length human MARK4 assessed as residual activity at 10 uM using KKKVSRSGLYRSPSMPENLNRPR as substrate incubated for 40 mins in presence of [gamma-33ATP by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	95.0	CHEMBL5754	Homo sapiens	Activity	%	95.0
	23120668	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	39800.0	CHEMBL5754	Homo sapiens	IC50	uM	39.8
	23120669	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	IC50	nM	23100.0	CHEMBL5754	Homo sapiens	IC50	uM	23.1
	23120670	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1	Outside typical range	CHEMBL4867931	=	IC50	nM	-500.0	CHEMBL5754	Homo sapiens	IC50	uM	-0.5
	23120671	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	IC50	nM	22200.0	CHEMBL5754	Homo sapiens	IC50	uM	22.2
	23120672	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4868141	=	IC50	nM	-1100.0	CHEMBL5754	Homo sapiens	IC50	uM	-1.1
	23120673	CHEMBL4804428	Inhibition of MARK4 in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	>	IC50	nM	75000.0	CHEMBL5754	Homo sapiens	IC50	uM	75.0
Not Determined	23121707	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542		Inhibition	%		CHEMBL5754	Homo sapiens	INH		
	23121708	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	INH	%	0.0
	23121709	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	INH	%	0.0
	23121710	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	INH	%	0.0
	23121711	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	0.0	CHEMBL5754	Homo sapiens	INH	%	0.0
	23121712	CHEMBL4804610	Inhibition of MARK4 in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	75.0	CHEMBL5754	Homo sapiens	INH	%	75.0
	23122663	CHEMBL4805014	Inhibition of human MARK4 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	78.0	CHEMBL5754	Homo sapiens	Activity	%	78.0
	23123358	CHEMBL4805602	Inhibition of human MARK4 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	95.0	CHEMBL5754	Homo sapiens	Activity	%	95.0
	23123817	CHEMBL4806061	Inhibition of DNA-tagged human MARK4 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	77.0	CHEMBL5754	Homo sapiens	Activity	%	77.0
	23124806	CHEMBL4806619	Inhibition of human MARK4 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL5754	Homo sapiens	Activity	%	100.0
	23124807	CHEMBL4806619	Inhibition of human MARK4 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	98.0	CHEMBL5754	Homo sapiens	Activity	%	98.0
	23128281	CHEMBL4807902	Inhibition of MARK4 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL5754	Homo sapiens	Activity	%	75.0
	23128282	CHEMBL4807902	Inhibition of MARK4 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL5754	Homo sapiens	Activity	%	75.0
	23128283	CHEMBL4807902	Inhibition of MARK4 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL5754	Homo sapiens	Activity	%	75.0
	23234022	CHEMBL4827601	Inhibition of wild-type human partial length MARK4 (K29 to G340 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	O=C(O)c1ccc(-c2cnn3ccccc23)cc1C1CCCC1		CHEMBL4851925	<	Activity	%	10.0	CHEMBL5754	Homo sapiens	Activity	%	10.0
Not Active	23317498	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23317966	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	88.0	CHEMBL5754	Homo sapiens	% Control	%	88.0
Not Active	23318633	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	56.0	CHEMBL5754	Homo sapiens	% Control	%	56.0
Not Active	23319116	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23319753	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	98.3	CHEMBL5754	Homo sapiens	% Control	%	98.3
Not Active	23320228	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	93.0	CHEMBL5754	Homo sapiens	% Control	%	93.0
Not Active	23320906	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23321374	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23322004	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	97.0	CHEMBL5754	Homo sapiens	% Control	%	97.0
Not Active	23322472	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23323161	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	92.0	CHEMBL5754	Homo sapiens	% Control	%	92.0
Not Active	23323629	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	88.0	CHEMBL5754	Homo sapiens	% Control	%	88.0
Not Active	23324483	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23325118	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	96.0	CHEMBL5754	Homo sapiens	% Control	%	96.0
Not Active	23325586	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23326233	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23326701	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	82.0	CHEMBL5754	Homo sapiens	% Control	%	82.0
Not Active	23327401	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23327869	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23328456	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23328924	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	97.0	CHEMBL5754	Homo sapiens	% Control	%	97.0
Not Active	23329413	CHEMBL4881120	MARK4(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	100.0	CHEMBL5754	Homo sapiens	% residual kinase activity	%	100.0
Not Active	23329870	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23330338	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23331094	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23331562	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	84.0	CHEMBL5754	Homo sapiens	% Control	%	84.0
Not Active	23332149	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	92.4	CHEMBL5754	Homo sapiens	% Control	%	92.4
Not Active	23332615	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	84.8	CHEMBL5754	Homo sapiens	% Control	%	84.8
Not Active	23333333	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23333972	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23334440	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23335419	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23335887	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23336514	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	94.0	CHEMBL5754	Homo sapiens	% Control	%	94.0
Not Active	23336982	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	85.0	CHEMBL5754	Homo sapiens	% Control	%	85.0
Not Active	23337677	CHEMBL4882048	MARK4 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	103.5	CHEMBL5754	Homo sapiens	% Ctrl	%	103.5
Not Active	23338063	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	95.0	CHEMBL5754	Homo sapiens	% Control	%	95.0
Not Active	23338531	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	96.0	CHEMBL5754	Homo sapiens	% Control	%	96.0
Not Active	23339143	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23339611	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23340248	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23340716	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	78.0	CHEMBL5754	Homo sapiens	% Control	%	78.0
Not Active	23341373	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23341841	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23342457	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23342925	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	82.0	CHEMBL5754	Homo sapiens	% Control	%	82.0
Not Active	23343555	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	79.0	CHEMBL5754	Homo sapiens	% Control	%	79.0
Not Active	23344023	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23344661	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23345234	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	99.0	CHEMBL5754	Homo sapiens	% Control	%	99.0
Not Active	23345702	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23346279	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23346747	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	71.5	CHEMBL5754	Homo sapiens	% Control	%	71.5
Not Active	23347349	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	96.0	CHEMBL5754	Homo sapiens	% Control	%	96.0
Not Active	23347839	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23348418	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23348886	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23349473	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23350091	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23350559	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23351164	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23351632	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23352130	CHEMBL4882819	MARK4 Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	15.65	CHEMBL5754	Homo sapiens	% Inhibition	%	15.6495
Not Active	23352656	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23353124	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23354006	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23354474	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	97.0	CHEMBL5754	Homo sapiens	% Control	%	97.0
Not Active	23355206	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23355674	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23356310	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23356778	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23357387	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23358034	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	76.0	CHEMBL5754	Homo sapiens	% Control	%	76.0
Not Active	23358502	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23359088	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	89.2	CHEMBL5754	Homo sapiens	% Control	%	89.2
Not Active	23359686	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	99.0	CHEMBL5754	Homo sapiens	% Control	%	99.0
Not Active	23360154	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23360739	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	88.0	CHEMBL5754	Homo sapiens	% Control	%	88.0
Not Active	23361207	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	79.0	CHEMBL5754	Homo sapiens	% Control	%	79.0
Not Active	23361780	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	80.0	CHEMBL5754	Homo sapiens	% Control	%	80.0
Not Active	23362316	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	77.0	CHEMBL5754	Homo sapiens	% Control	%	77.0
Not Active	23362784	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	83.0	CHEMBL5754	Homo sapiens	% Control	%	83.0
Not Active	23364426	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	83.0	CHEMBL5754	Homo sapiens	% Control	%	83.0
Not Active	23364894	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	85.0	CHEMBL5754	Homo sapiens	% Control	%	85.0
Not Active	23365633	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	76.0	CHEMBL5754	Homo sapiens	% Control	%	76.0
Not Active	23366176	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23366766	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	76.0	CHEMBL5754	Homo sapiens	% Control	%	76.0
Not Active	23367234	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	98.0	CHEMBL5754	Homo sapiens	% Control	%	98.0
Not Active	23367636	CHEMBL4883989	MARK4 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	96.0	CHEMBL5754	Homo sapiens	% Residual activity with Skepinone-L	%	96.0
Not Active	23368112	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	91.0	CHEMBL5754	Homo sapiens	% Control	%	91.0
Not Active	23368580	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	86.0	CHEMBL5754	Homo sapiens	% Control	%	86.0
Not Active	23369179	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23369647	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23370134	CHEMBL4884378	MARK4(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	65.0	CHEMBL5754	Homo sapiens	% residual kinase activity	%	65.0
Not Active	23370615	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	51.0	CHEMBL5754	Homo sapiens	% Control	%	51.0
Not Active	23371083	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	94.0	CHEMBL5754	Homo sapiens	% Control	%	94.0
Not Active	23371892	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23372360	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	71.0	CHEMBL5754	Homo sapiens	% Control	%	71.0
Not Active	23375787	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23376255	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	99.0	CHEMBL5754	Homo sapiens	% Control	%	99.0
Not Active	23376832	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23377300	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23378160	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	84.0	CHEMBL5754	Homo sapiens	% Control	%	84.0
Not Active	23378628	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	92.0	CHEMBL5754	Homo sapiens	% Control	%	92.0
Not Active	23379795	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	98.0	CHEMBL5754	Homo sapiens	% Control	%	98.0
Not Active	23380263	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	90.0	CHEMBL5754	Homo sapiens	% Control	%	90.0
Not Active	23380957	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23381605	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23382073	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	100.0	CHEMBL5754	Homo sapiens	% Control	%	100.0
Not Active	23382697	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	83.0	CHEMBL5754	Homo sapiens	% Control	%	83.0
Not Active	23383165	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	63.0	CHEMBL5754	Homo sapiens	% Control	%	63.0
Not Active	23383884	CHEMBL4887502	MARK4 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	100.0	CHEMBL5754	Homo sapiens	% Ctrl	%	100.0
Not Active	23384340	CHEMBL4887935	MARK4(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	5.8	CHEMBL5754	Homo sapiens	% inhibition	%	5.8
Not Active	23385080	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	76.0	CHEMBL5754	Homo sapiens	% Control	%	76.0
Not Active	23385547	CHEMBL4879804	KinomeScan assay: inhibition of MARK4	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	89.0	CHEMBL5754	Homo sapiens	% Control	%	89.0
